Lifitegrast-containing ink binder for ophthalmic devices
A lifitegrast-containing film on ophthalmic devices, formed using an ink binder with polymerizable reactive groups and releasable linking groups, addresses inefficiencies in conventional delivery methods by providing sustained and controlled drug release, improving treatment efficacy for dry eye disease.
Patent Information
- Application Number
- PCT/EP2026/063064
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Conventional methods for delivering lifitegrast or its salt to treat dry eye disease, such as eye drops and ointments, are inefficient, leading to poor patient compliance and incorrect dosing, while advanced formulations like gels and colloidal systems have not achieved satisfactory outcomes in terms of sustained drug delivery.
A lifitegrast-containing ink binder is applied to form a film on an ophthalmic device, which includes a solvent, an ink binder polymer with polymerizable ethylenically unsaturated reactive groups, and lifitegrast or its salt with releasable linking groups, allowing for a sustained release of lifitegrast or its salt to the eye through light or enzymatic activation.
The lifitegrast-containing film provides significantly greater drug bioavailability and controlled release, enhancing treatment efficacy for dry eye disease by ensuring continuous and sustained delivery of lifitegrast to the cornea.
Smart Images

Figure IMGF000009_0001 
Figure IMGF000011_0001 
Figure IMGF000016_0001
Abstract
Description
LIFITEGRAST-CONTAINING INK BINDER FOR OPHTHALMIC DEVICES PRIORITY CLAIM
[0001] The present application claims priority to U.S. Provisional Patent Application Serial No. 63 / 801,294, entitled “Lifitegrast-Containing Ink Binder for Ophthalmic Devices,” filed May 7, 2025, the content of which is incorporated by reference herein in its entirety.BACKGROUND
[0002] For cosmetic purposes, contact lenses having one or more colorants dispersed in the lens or printed on the lens are in high demand. These colored contact lenses enhance the natural beauty of the eye, or provide unique patterns on the iris of the wearer, or provide non cosmetic patterns or marks, such as rotation marks, inversion marks, product / brand codes, lot numbers, “DEMO” lenses, and the like, which are of benefits to wearers, eye-care practitioners and manufacturers.SUMMARY
[0003] In accordance with one aspect of the present disclosure, a lifitegrast-containing ink binder comprises:
[0004] (a) a solvent,
[0005] (b) an ink binder polymer comprising a polymerizable ethylenically unsaturated reactive group, and
[0006] (c) one or more of a lifitegrast or a salt thereof, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group and a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group.
[0007] In accordance with another aspect of the present disclosure, an ophthalmic device comprises a lifitegrast-containing film on at least a portion of a surface thereof, the lifitegrast-containing film comprising a polymerization product of a lifitegrast-containing ink binder comprising (a) a solvent, (b) an ink binder polymer comprising a polymerizable ethylenically unsaturated reactive group, and (c) one or more of a lifitegrast or a salt thereof, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group and optionally anethylenically unsaturated reactive group and a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group.
[0008] In accordance with yet another aspect of the present disclosure, a method comprises:
[0009] (a) applying, to at least a portion of a molding surface of an ophthalmic device mold, a lifitegrast-containing ink binder comprising:
[0010] (1) a solvent,
[0011] (ii) an ink binder polymer comprising a polymerizable ethylenically unsaturated reactive group, and
[0012] (iii) one or more of a lifitegrast or a salt thereof, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group and a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group, and
[0013] (b) curing the lifitegrast-containing ink binder to form a lifitegrast-containing film which comprises a polymer network with the one or more of the lifitegrast or salt thereof, the lifitegrast or salt thereof-containing monomer and the lifitegrast or salt thereof-containing polymer in the polymer network, wherein the lifitegrast-containing film contains a first surface in contact with the molding surface and an exposed second surface.
[0014] In accordance with still yet another aspect of the present disclosure, a method comprises:
[0015] (a) applying, to at least a portion of a molding surface of an ophthalmic device mold, a lifitegrast-containing ink binder comprising (i) a solvent, (ii) an ink binder polymer comprising a polymerizable ethylenically unsaturated reactive group, and (iii) one or more of a lifitegrast or a salt thereof, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group and a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group,
[0016] (b) curing the lifitegrast-containing ink binder to form a lifitegrast-containing film which comprises a polymer network with the one or more of the lifitegrast or salt thereof, the lifitegrast or salt thereof-containing monomer and the lifitegrast or salt thereof-containing polymerin the polymer network, wherein the lifitegrast-containing film contains a first surface in contact with the molding surface and an exposed second surface,
[0017] (c) dispensing an ophthalmic device-forming mixture comprising one or more ophthalmic device-forming material into the ophthalmic device mold having the lifitegrast-containing film, and
[0018] (d) curing the ophthalmic device-forming mixture comprising the ophthalmic device-forming material to form an ophthalmic device, whereby the lifitegrast-containing film detaches from the molding surface and becomes integral with the body of the ophthalmic device thereby producing an ophthalmic device having the lifitegrast-containing film on at least a portion of a surface thereof.
[0019] In accordance with still yet a further aspect of the present disclosure, a method for delivering lifitegrast or a salt thereof to an eye of a subject comprises:
[0020] (a) placing an ophthalmic device having a lifitegrast-containing film on at least a portion of a surface thereof in an eye of a subject, wherein the lifitegrast-containing film comprises a polymerization product of a lifitegrast-containing ink binder comprising (i) a solvent, (ii) an ink binder polymer comprising a polymerizable ethylenically unsaturated reactive group, and (iii) one or more of a lifitegrast or a salt thereof, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group and a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and an ethylenically unsaturated reactive group, and
[0021] (b) delivering the lifitegrast or salt thereof to the eye of the subject.DETAILED DESCRIPTION
[0022] Various illustrative embodiments described herein include a lifitegrast-containing ink binder and an ophthalmic device having a lifitegrast-containing film on at least a portion of a surface thereof made therefrom for delivering the lifitegrast or salt thereof to the eye of the subject to treat, for example, dry eye.
[0023] DEFINITIONS
[0024] To define more clearly the terms used herein, the following definitions are provided. Unless otherwise indicated, the following definitions are applicable to this disclosure.If a term is used in this disclosure but is not specifically defined herein, the definition from the IUPAC Compendium of Chemical Terminology can be applied, as long as that definition does not conflict with any other disclosure or definition applied herein or render indefinite or non-enabled any claim to which that definition is applied. To the extent that any definition or usage provided by any document incorporated herein by reference conflicts with the definition or usage provided herein, the definition or usage provided herein controls.
[0025] A “prepolymer” refers to a starting polymer which can be cured (e.g., crosslinked and / or polymerized) actinically or thermally or chemically to obtain a crosslinked and / or polymerized polymer having a molecular weight higher than the molecular weight of the starting polymer.
[0026] A “crosslinkable prepolymer” refers to a starting polymer which can be crosslinked to obtain a crosslinked polymer having a molecular weight higher than the molecular weight of the starting polymer.
[0027] A “colorant” refers to either a dye or a pigment or a mixture thereof that is used to print a color image on an article.
[0028] A “dye” refers to a substance that is soluble in a solvent and that is used to impart color. A dye is typically translucent and absorb but do not scatter light. A dye can cover both optical regions of contact lenses and non-optical regions of contact lenses. Nearly any dye can be used in the present disclosure, so long as it can be used in an apparatus as described below. These dyes include fluorescent dyes, phosphorescent dyes, and conventional dyes.
[0029] A “pigment” refers to a powdered substance that is suspended in a liquid in which it is insoluble. A pigment can be used to impart color. Pigments, in general, are more opaque than dyes.
[0030] The term “hydrogel” or “hydrogel material” as used herein refers to a crosslinked polymeric material that has a three-dimensional polymer network (i.e., polymer matrix), is insoluble in water, but can hold at least about 10 percent by weight of water in its polymer matrix when it is fully hydrated.
[0031] The term “silicone hydrogel” or “SiHy” as used herein interchangeably refers to a hydrogel containing silicone. A silicone hydrogel (SiHy) typically is obtained bycopolymerization of a polymerizable composition comprising at least one ophthalmic deviceforming material.
[0032] The term “(meth)” as used herein denotes an optional methyl substituent. Thus, terms such as “(meth)acrylate” denotes either methacrylate or acrylate, and “(meth)acrylamide” denotes either methacrylamide or acrylamide.
[0033] While compositions and processes are described in terms of “comprising” various components or steps, the compositions and processes can also “consist essentially of’ or “consist of’ the various components or steps, unless stated otherwise.
[0034] The terms “a,” “an,” and “the” are intended to include plural alternatives, e.g., at least one. The terms “including,” “with,” and “having,” as used herein, are defined as comprising (i.e., open language), unless specified otherwise.
[0035] Various numerical ranges are disclosed herein. When Applicant discloses or claims a range of any type, Applicant’s intent is to disclose or claim individually each possible number that such a range could reasonably encompass, including end points of the range as well as any sub-ranges and combinations of sub-ranges encompassed therein, unless otherwise specified. For example, all numerical end points of ranges disclosed herein are approximate, unless excluded by proviso.
[0036] Values or ranges may be expressed herein as “about,” from “about” one particular value, and / or to “about” another particular value. When such values or ranges are expressed, other embodiments disclosed include the specific value recited, from the one particular value, and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that there are a number of values disclosed therein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. In another aspect, use of the term “about” means ±20% of the stated value, ±15% of the stated value, ±10% of the stated value, ±5% of the stated value, ±3% of the stated value, or ±1% of the stated value.
[0037] The terms “wt. %,” “vol. %” or “mol. %” refers to a weight, volume, or molar percentage of a component, respectively, based on the total weight, the total volume, or the total moles of material that includes the component. In a non-limiting example, 10 moles of component in 100 moles of the material are 10 mol. % of component.
[0038] Applicant reserves the right to proviso out or exclude any individual members of any such group of values or ranges, including any sub-ranges or combinations of sub-ranges within the group, that can be claimed according to a range or in any similar manner, if for any reason Applicant chooses to claim less than the full measure of the disclosure, for example, to account for a reference that Applicant may be unaware of at the time of the filing of the application. Further, Applicant reserves the right to proviso out or exclude any members of a claimed group.
[0039] As used herein, the term “ophthalmic device” refers to devices that reside in or on the eye. These ophthalmic devices can provide optical correction, wound care, drug delivery, diagnostic functionality or cosmetic enhancement or effect or a combination of these properties. Representative examples of such devices include, but are not limited to, soft contact lenses, e.g., a soft, hydrogel lens; soft, non-hydrogel lens and the like, hard contact lenses, e.g., a hard, gas permeable lens material and the like, intraocular lenses, overlay lenses, ocular inserts, optical inserts and the like. As is understood by one skilled in the art, a lens is considered to be “soft” if it can be folded back upon itself without breaking. A contact lens can be in a dry state or a wet state. A “dry state” refers to a soft contact lens in a state prior to hydration or the state of a hard lens under storage or use conditions. A “wet state” refers to a soft contact lens in a hydrated state.
[0040] Ophthalmic drug delivery faces significant obstacles due to anatomical and physiological barriers, such as tear drainage and limited epithelial transport, which restrict drug bioavailability to around 5% or less. These barriers impede the penetration and absorption of therapeutic agents, making effective treatment challenging. An optimal delivery system must address these issues by enhancing bioavailability and enabling controlled drug release at the target site.
[0041] Lifitegrast or a salt thereof is a well-established medication for the treatment of dry eye disease. Ophthalmic lifitegrast or salt thereof is specifically used to alleviate the signs and symptoms associated with this condition. Classified as a lymphocyte function-associated antigen-1 (LFA-1) antagonist, lifitegrast or salt thereof functions by reducing inflammation in the eye tissues.
[0042] Conventional methods like eye drops and ointments have been used to deliver lifitegrast or a salt thereof. However, these delivery methods are inefficient, requiring frequent applications and often resulting in poor patient compliance and incorrect dosing. While advancedformulations such as gels, viscous solutions, and colloidal systems have been developed, they have yet to achieve satisfactory outcomes.
[0043] The non-limiting illustrative embodiments disclosed herein overcome the foregoing drawbacks by providing an ophthalmic device having a lifitegrast-containing film on at least a portion of a surface thereof that can deliver lifitegrast or a salt thereof to the eye of the user in a continuous and sustained release manner. By providing significantly greater drug bioavailability to the cornea compared to the traditional methods discussed above, the ophthalmic devices of the non-limiting illustrative embodiments described herein can be utilized as a controlled drug delivery platform. This can be achieved by utilizing a lifitegrast-containing ink binder for forming a lifitegrast-containing film on at least a portion of a surface of the ophthalmic device. In some embodiments, the lifitegrast or salt thereof can be embedded in the lifitegrast-containing film which allows the lifitegrast or salt thereof to be released in a sustained release manner to the eye of the subject. In some embodiments, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group or a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group can be embedded in the lifitegrast-containing film thereby releasing the lifitegrast or salt thereof by contacting the lifitegrast-containing film with one of light having a wavelength of about 300 nanometers (nm) to about 700 nm or with an esterases or enzymes on the eye in a tear film or on a flora of the eye. In some embodiments, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group or a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and an ethylenically unsaturated reactive group can be attached to the ink binder polymer comprising a polymerizable ethylenically unsaturated reactive group such that the lifitegrast or salt thereof is released by contacting the lifitegrast-containing film with one of light having a wavelength of about 300 nm to about 700 nm or with an esterases or enzymes on the eye, in a tear film or on a flora of the eye.
[0044] Lifitegrast-Containing Ink Binder
[0045] In non-limiting illustrative embodiments, a lifitegrast-containing ink binder of the present disclosure includes (a) a solvent, (b) an ink binder polymer comprising a polymerizable ethylenically unsaturated reactive group, and (c) one or more of a lifitegrast or a salt thereof, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group andoptionally an ethylenically unsaturated reactive group and a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and an ethylenically unsaturated reactive group.
[0046] 1. Solvent
[0047] In some embodiments, a solvent can be water, an organic or inorganic solvent, a mixture of several organic solvents, or a mixture of water and one or more water soluble or water miscible organic solvents. Any known solvents can be used, so long as they can dissolve the ink binder polymer in the lifitegrast-containing ink binder of the present disclosure and aid in the stability of the colorant when used. Suitable solvents include, for example, water, acetone, alcohols (e.g., methanol, ethanol, propanol, isopropanol, 2-ethy oxy ethanol, etc.), glycols, ketones, esters, cyclopentanone, cyclohexanone, tetrahydrofuran, acetone, methyl-2-pyrrolidone, dimethyl formamide, acetophenone, methylene dichloride, dimethyl sulfoxide, gamma-butyrolactone, ethylene dichloride, isophorone, o-dichlorobenzene, tetrahydrofuran, diacetone alcohol, methyl ethyl ketone, acetone, 2-nitropropane, ethylene glycol monoethyl ether, propylene carbonate, cyclohexanol, chloroform, trichloroethylene, 1,4-di oxane, ethyl acetate, ethyl lactate, ethylene glycol monobutyl ether, chlorobenzene, nitroethane, ethylene glycol monomethyl ether, butyl acetate, 1 -butanol, methyl isobutyl ketone, nitromethane, toluene, ethanol, di ethylene glycol, benzene, diethyl ether, ethanolamine, carbon tetrachloride, propylene glycol, hexane, ethylene glycol, and formamide.
[0048] 2, Ink Binder Polymer
[0049] In non-limiting illustrative embodiments, the ink binder further includes an ink binder polymer comprising a polymerizable ethylenically unsaturated reactive group. In one embodiment, an ink binder polymer comprising a polymerizable ethylenically unsaturated reactive group can include a reaction product of (i) a copolymer comprising (1) monomeric units derived from a hydroxyalkyl acrylate monomer, and (2) monomeric units derived from a hydrophilic monomer having an ethylenically unsaturated reactive group, with (ii) a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive end group.
[0050] In some embodiments, a hydroxyalkyl acrylate monomer for use in copolymer includes hydroxy Ci to Ce acrylate monomers. In some embodiments, a hydroxyalkyl acrylate monomer for use in the polymerization composition is represented by the following structure:
[0051] In some embodiments, a hydrophilic monomer having an ethylenically unsaturated reactive group for use in the copolymer includes, for example, unsaturated carboxylic acids, acrylamides, vinyl lactams, hydroxyl-containing (meth)acrylates, hydrophilic vinyl carbonates, hydrophilic vinyl carbamates, hydrophilic oxazolones, and poly(alkene glycols) functionalized with polymerizable groups and the like and mixtures thereof. Representative examples of unsaturated carboxylic acids include methacrylic acid, acrylic acid and the like and mixtures thereof. Representative examples of amides include alkylamides such as N,N-dimethylacrylamide, N,N-dimethylmethacrylamide and the like and mixtures thereof. Representative examples of cyclic lactams include N-vinyl-2-pyrrolidone, N-vinyl caprolactam, N-vinyl-2-piperidone and the like and mixtures thereof. Representative examples of hydroxyl-containing (meth)acrylates include 2-hydroxyethyl methacrylate (HEMA), glycerol methacrylate and the like and mixtures thereof. Still further examples are the hydrophilic vinyl carbonate or vinyl carbamate monomers disclosed in U.S. Patent No. 5,070,215, and the hydrophilic oxazolone monomers disclosed in U.S. Patent No. 4,910,277. Other suitable hydrophilic monomers will be apparent to one skilled in the art. Mixtures of the foregoing hydrophilic monomers can also be used in the monomeric mixtures herein.
[0052] In some embodiments, a hydrophilic monomer having an ethylenically unsaturated reactive group can be vinyl chloro formate. The vinyl chloro formate has vinyl groups for attaching to the backbone of the copolymer and a chloro group can be subsequently reacted with an OH group or an amine group to provide a functional derivative, e.g., vinyl chloroformate (Cl-COOCH=CH2) that can provide a -NH-COOCH=CH2 functional derivative or a -O-COOCH=CH2 functional derivative depending on the reaction with the NH2- or OH- group, respectively.
[0053] In some embodiments, a copolymer comprises (i) monomeric units derived from hydroxyalkyl acrylate, and (ii) monomeric units derived from N-vinyl-2 -pyrrolidone.
[0054] The copolymers can be prepared using free radical polymerization techniques with the structure of the polymer being completely random or controlled by the reactivity ratios of the respective monomers.
[0055] In some embodiments, a random copolymer can be obtained by (1) mixing the hydroxyalkyl acrylate and the hydrophilic monomer, (2) adding a polymerization initiator, (3) and subjecting the monomer / initiator mixture to a source of heat. The amount of the hydroxyalkyl acrylate in the mixture can range from about 10 mol % to about 25 mol % and the amount of the hydrophilic monomer can range from about 75 mol % to about 90 mol %.
[0056] Suitable initiators include free-radical-generating polymerization initiators of the type illustrated by acetyl peroxide, lauroyl peroxide, decanoyl peroxide, caprylyl peroxide, benzoyl peroxide, tertiary butyl peroxypivalate, sodium percarbonate, tertiary butyl peroctoate, and azobis-isobutyronitrile (AIBN). A level of initiator employed will vary within the range of 0.01 wt. % to 2 wt. %, based on the total weight of the mixture. If desired, the mixture of the above-mentioned monomers is warmed with addition of a free-radical former.
[0057] In some embodiments, the reaction can be carried out until all of the hydroxyalkyl acrylate has been reacted. Suitable polymerization conditions include, for example, a temperature of between about 15°C to about 120°C for a time period of about 30 minutes to about 48 hours. If desired, the reaction can be carried out in the presence of a suitable solvent. Suitable solvents are in principle all solvents which dissolve the monomers used including, for example, 1 ,4-di oxane, hexanol, dimethylformamide; acetone, cyclohexanone, toluene, and the like and mixtures thereof.
[0058] The copolymers disclosed herein can be prepared using techniques of controlled radical polymerization, e.g., by reversible addition-fragmentation chain transfer (RAFT) polymerization or atom-transfer radical polymerization (ATRP) employing a chain transfer agent that allows construction of copolymers with a well-defined molecular weight distribution and narrow polydispersity. RAFT polymerization is particularly preferred because it is compatible with a wide variety of vinyl monomers.
[0059] In non-limiting illustrative embodiments, the RAFT agents suitable for use herein can be based upon thio carbonyl thio chemistry which is well known to those of ordinary skill in the art. The thio carbonyl thio fragment can be derived from a RAFT agent such as, for example, a xanthate-containing compound, trithiocarbonate-containing compound, dithiocarbamate-containing compound, a dithiobenzoate-containing compound or dithio ester-containing compound, wherein each compound contains a thio carbonyl thio group. One class of RAFT agents that can be used herein is of the general formula:wherein x is 1 or 2, Z is a substituted oxygen (e.g., xanthates (-O-R)), a substituted nitrogen (e.g., dithiocarbamates (-NRR)), a substituted sulfur (e.g., trithiocarbonates (-S-R)), a dithiobenzoate, a substituted or unsubstituted C1-C20 alkyl or C3-C25 unsaturated, or partially or fully saturated ring (e.g., dithioesters (-R)) or carboxylic acid-containing group; and R is independently a straight or branched, substituted or unsubstituted C1-C30 alkyl cyano group, a straight or branched, substituted or unsubstituted C1-C30 alkyl group, a substituted or unsubstituted C3-C30 cycloalkyl group, a substituted or unsubstituted C3-C30 cycloalkylalkyl group, a substituted or unsubstituted C3-C30 cycloalkenyl group, a substituted or unsubstituted C5-C30 aryl group, a substituted or unsubstituted C5-C30 arylalkyl group, a C1-C20 ester group; an ether or polyether-containing group; an alkyl- or arylamide group; an alkyl- or arylamine group; a substituted or unsubstituted C5-C30 heteroaryl group; a substituted or unsubstituted C3-C30 heterocyclic ring; a substituted or unsubstituted C4-C30 heterocycloalkyl group; a substituted or unsubstituted C6-C30 heteroarylalkyl group; and combinations thereof.
[0060] Representative examples of alkyl groups for use herein include, by way of example, a straight or branched alkyl chain radical containing carbon and hydrogen atoms of from 1 to about 30 carbon atoms and preferably from 1 to about 12 carbon atoms with or without unsaturation, to the rest of the molecule, e.g., methyl, ethyl, n-propyl, 1 -methylethyl (isopropyl), n-butyl, n-pentyl, methylene, ethylene, etc., and the like.
[0061] Representative examples of cycloalkyl groups for use herein include, by way of example, a substituted or unsubstituted non-aromatic mono or multicyclic ring system of about 3 to about 30 carbon atoms and preferably from 3 to about 6 carbon atoms such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, perhydronapththyl, adamantyl and norbornyl groups, bridged cyclic groups or sprirobicyclic groups, e.g., spiro-(4, 4)-non-2-yl and the like, optionally containing one or more heteroatoms, e.g., O and N, and the like.
[0062] Representative examples of cycloalkylalkyl groups for use herein include, by way of example, a substituted or unsubstituted cyclic ring-containing radical containing from about 3to about 30 carbon atoms and preferably from 3 to about 6 carbon atoms directly attached to the alkyl group which are then attached to the main structure of the monomer at any carbon from the alkyl group that results in the creation of a stable structure such as, for example, cyclopropylmethyl, cyclobutylethyl, cyclopentylethyl and the like, wherein the cyclic ring can optionally contain one or more heteroatoms, e.g., O and N, and the like.
[0063] Representative examples of cycloalkenyl groups for use herein include, by way of example, a substituted or unsubstituted cyclic ring-containing radical containing from about 3 to about 30 carbon atoms and preferably from 3 to about 6 carbon atoms with at least one carboncarbon double bond such as, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl and the like, wherein the cyclic ring can optionally contain one or more heteroatoms, e.g., O and N, and the like.
[0064] Representative examples of aryl groups for use herein include, by way of example, a substituted or unsubstituted monoaromatic or polyaromatic radical containing from about 5 to about 30 carbon atoms such as, for example, phenyl, naphthyl, tetrahydronapthyl, indenyl, biphenyl and the like, optionally containing one or more heteroatoms, e.g., O and N, and the like.
[0065] Representative examples of arylalkyl groups for use herein include, by way of example, a substituted or unsubstituted aryl group as defined herein directly bonded to an alkyl group as defined herein, e.g., -CH2C6H5, -C2H5C6H5 and the like, wherein the aryl group can optionally contain one or more heteroatoms, e.g., O and N, and the like.
[0066] Representative examples of ester groups for use herein include, by way of example, a carboxylic acid ester having one to 20 carbon atoms and the like.
[0067] Representative examples of ether or polyether containing groups for use herein include, by way of example, an alkyl ether, cycloalkyl ether, cycloalkylalkyl ether, cycloalkenyl ether, aryl ether, arylalkyl ether wherein the alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, and arylalkyl groups are as defined herein. Exemplary ether or polyether-containing groups include, by way of example, alkylene oxides, poly(alkylene oxide)s such as ethylene oxide, propylene oxide, butylene oxide, poly(ethylene oxide)s, poly(ethylene glycol)s, poly(propylene oxide)s, poly(butylene oxide)s and mixtures or copolymers thereof, an ether or polyether group of the general formula -(R2OR3)t, wherein R2is a bond, a substituted or unsubstituted alkyl, cycloalkyl or aryl group as defined herein and R3is a substituted or unsubstituted alkyl, cycloalkylor aryl group as defined herein and t is at least 1, e.g., -CH2CH2OC6H5 and CH2-CH2-CH2-O-CH2-(CF2)Z-H where z is 1 to 6, -CH2CH2OC2H5, and the like.
[0068] Representative examples of alkyl or arylamide groups for use herein include, by way of example, an amide of the general formula -R4C(O)NR5R6wherein R4, R5and R6are independently C1-C30 hydrocarbons, e.g., R4can be alkylene groups, arylene groups, cycloalkylene groups and R5and R6can be alkyl groups, aryl groups, and cycloalkyl groups as defined herein and the like.
[0069] Representative examples of alkyl or arylamine groups for use herein include, by way of example, an amine of the general formula -R7N R8R9wherein R7is a C2-C30 alkylene, arylene, or cycloalkylene and R8and R9are independently C1-C30 hydrocarbons such as, for example, alkyl groups, aryl groups, or cycloalkyl groups as defined herein.
[0070] Representative examples of heterocyclic ring groups for use herein include, by way of example, a substituted or unsubstituted stable 3 to about 30 membered ring radical, containing carbon atoms and from one to five heteroatoms, e.g., nitrogen, phosphorus, oxygen, sulfur and mixtures thereof. Suitable heterocyclic ring radicals for use herein may be a monocyclic, bicyclic or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized; and the ring radical may be partially or fully saturated (i.e., heteroaromatic or heteroaryl aromatic).
[0071] Representative examples of heteroaryl groups for use herein include, by way of example, a substituted or unsubstituted heterocyclic ring radical as defined herein. The heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
[0072] Representative examples of heteroarylalkyl groups for use herein include, by way of example, a substituted or unsubstituted heteroaryl ring radical as defined herein directly bonded to an alkyl group as defined herein. The heteroarylalkyl radical may be attached to the main structure at any carbon atom from the alkyl group that results in the creation of a stable structure.
[0073] Representative examples of heterocyclic groups for use herein include, by way of example, a substituted or unsubstituted heterocylic ring radical as defined herein. The heterocyclicring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
[0074] The substituents in the ‘substituted oxygen’, ‘substituted nitrogen’, ‘substituted sulfur’, ‘substituted alkyl’, ‘substituted alkylene, ‘substituted cycloalkyl’, ‘substituted cycloalkylalkyl’, ‘substituted cycloalkenyl’, ‘substituted arylalkyl’, ‘substituted aryl’, ‘substituted heterocyclic ring’, ‘substituted heteroaryl ring,’ ‘substituted heteroarylalkyl’, ‘substituted heterocycloalkyl ring’, ‘substituted cyclic ring’ may be the same or different and include one or more substituents such as hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio(=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted heterocycloalkyl ring, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, and the like.
[0075] Representative examples of RAFT agents for use herein include, but are not limited to, 4-cyano-4-(dodecyl-sulfanylthiocarbonyl)sulfanylpentanoic acid, S-cyanomethyl-5-dodecyltrithiocarbonate, S-(2-cyano-2-propyl)-S-dodecyltrithiocarbonate, 3-benzylsulfanylthiocarbonylsulfanyl-propionic acid, cumyl dithiobenzoate, 2-cyanoprop-2-yl dithiobenzoate (i.e., cyanoisopropyl dithiobenzoate), 4-thiobenzoylsulfanyl-4-cyanopentanoic acid (TCA), S,S’-bis(a,a’-dimethyl-alpha”-acetic acid)-trithiocarbonate (BATC), benzyl dodecyl trithiocarbonate, ethyl-2-dodecyl trithiocarbony) proprionate, S-sec propionic acid O-ethyl xanthate, a-ethyl xanthylphenylacetic acid, ethyl a-(o-ethyl xanthyl) proprionate, ethyl a-(ethyl xanthyl) phenyl acetate, ethyl 2-(dodecyl trithiocarbonyl) phenyl acetate, ethyl 2-(dodecyl trithiocarbonyl) propionate, 2-(dodecylthiocarbonylthiol)propanoic acid, and the like and mixtures thereof.
[0076] There is no particular limitation on the organic chemistry used to form the RAFT agent and is within the purview of one skilled in the art.
[0077] The copolymers disclosed herein can be obtained in a first step (a) by (1) mixing either the hydroxyalkyl acrylate monomer or the hydrophilic monomer with a RAFT agent; (2) adding a polymerization initiator; (3) and subjecting the monomer / RAFT agent / initiator mixtureto a source of heat. Suitable initiators include, for example, free-radical-generating polymerization initiators of the type illustrated by acetyl peroxide, lauroyl peroxide, decanoyl peroxide, coprylyl peroxide, benzoyl peroxide, tertiary butyl peroxypivalate, sodium percarbonate, tertiary butyl peroctoate, and azobisisobutyronitrile (AIBN).
[0078] The reaction can be carried out at a temperature of between about 15°C to about 120°C for a time period of about 30 minutes to about 48 hours. If desired, the reaction can be carried out in the presence of a suitable solvent. Suitable solvents are in principle all solvents which dissolve the monomer used, for example, 1,4-di oxane, hexanol, dimethylformamide; acetone, cyclohexanone, toluene, and the like and mixtures thereof.
[0079] In an illustrative embodiment, the hydroxyalkyl acrylate monomer is employed in an amount ranging from about 1 wt. % to about 98 wt. %, based on the total weight of the mixture. In an illustrative embodiment, the RAFT agent is employed in an amount ranging from about 0.5 wt. % to about 3 wt. %, based on the total weight of the mixture. The level of initiator employed will vary within the range of 0.01 wt. % to 2 wt. % of the mixture of monomers. If desired, the mixture of the above-mentioned monomers is warmed with addition of a free-radical former.
[0080] Next, in a step (b) the resulting product of step (a) is then mixed with the other one of the hydroxyalkyl monomer or the hydrophilic monomer and an initiator and subjected to a source of heat as described above until the desired copolymer is formed. In an illustrative embodiment, the other one of the hydroxyalkyl acrylate monomer or the hydrophilic monomer is employed in an amount ranging from about 1 wt. % to about 95 wt. %, based on the total weight of the mixture. In an illustrative embodiment, the resulting product of step (a) is employed in an amount ranging from about 1 wt. % to about 20 wt. %, based on the total weight of the mixture.
[0081] A non-limiting schematic representation of a synthetic method for making a copolymer with a RAFT agent is set forth below in Scheme IScheme I
[0082] As one skilled in the art will readily appreciate, the copolymer disclosed herein can contain a balance of monomeric units derived from the hydroxyalkyl acrylate monomer and monomeric units derived from the hydrophilic monomer. In some embodiments, a copolymer can include from about 5 mol. % to about 95 mol % of repeating units of monomeric units derived from a hydroxyalkyl and from about 5 mol. % to about 95 mol % of repeating units of monomeric units derived from a hydrophilic monomer.
[0083] In some embodiments, the copolymer is thereafter reacted with a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive group to obtain a functionalized copolymer. The foregoing reaction will result in additional monomeric units derived from the hydroxyalkyl acrylate monomer with the hydroxy moiety being reacted with the reactive functionality of the monomer such that the hydroxyalkyl acrylate monomer contains an end functionalized group, i.e., a polymerizable ethylenically unsaturated reactive group.
[0084] In an illustrative embodiment, a polymerizable ethylenically unsaturated reactive group can be one or more of an acrylate end group and a methacrylate end group.
[0085] A suitable monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive group include, for example, 2-isocyanatoethyl acrylate, 3-isocyanatopropyl acrylate, 2-isocyanatoethyl methacrylate, 1 -methyl-2-isocyanatoethyl methacrylate, 1,1-dimethy 1-2-isocyanatoethyl acrylate, (meth)acryloyl chloride, vinyl chloroformate and the like.
[0086] In an illustrative embodiment, the copolymer is present in the reaction mixture in an amount ranging from about 70 wt. % to about 99 wt. %, based on the total weight of the reaction mixture. In an illustrative embodiment, the copolymerization product is present in the reactionmixture in an amount ranging from about 85 wt. % to about 99 wt. %, based on the total weight of the reaction mixture.
[0087] In an illustrative embodiment, the monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate and a polymerizable ethylenically unsaturated reactive group is present in the reaction mixture in an amount ranging from about 0.5 wt. % to about 30 wt. %, based on the total weight of the reaction mixture. In an illustrative embodiment, the monomer having a reactive functionality complementary to one of the one or more reactive functionalities of the hydrophilic monomer and a polymerizable ethylenically unsaturated reactive group is present in the reaction mixture in an amount ranging from about 1 wt. % to about 15 wt. %, based on the total weight of the reaction mixture.
[0088] The reaction of the copolymerization product and the monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate and a polymerizable ethylenically unsaturated reactive group can be carried out in the presence of a catalyst. Suitable catalysts include, for example, the stannous salts of carboxylic acids, such as stannous octoate, stannous oleate, stannous acetate, and stannous laurate, dialkyltin dicarboxylates, such as dibutyltin dilaurate and dibutyltin diacetate which are known in the art as urethane catalysts, as are tertiary amines and tin mercaptides. The amount of catalyst employed is generally between about 0.01 wt. % to about 5 wt. % of the mixture catalyzed.
[0089] The reaction can be carried out at a temperature of between about 60°C to about 100°C for about 2 hours to about 24 hours. The reaction can be carried out in the presence of a suitable solvent as discussed above.
[0090] Accordingly, in a non-limiting illustrative embodiment, a functionalized copolymer disclosed herein comprises:
[0091] (i) monomeric units derived from a hydroxyalkyl acrylate monomer,
[0092] (ii) monomeric units derived from a hydrophilic monomer having an ethylenically unsaturated reactive group, and
[0093] (iii) monomeric units derived from a hydroxyalkyl acrylate monomer where the acrylate moiety is attached to the backbone of the copolymer and the hydroxy moiety is end functionalized with monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate and a polymerizable ethylenically unsaturated reactive group.
[0094] In some embodiments, a functionalized copolymer disclosed herein includes:
[0095] from about 5 to about 200 repeating units of monomeric units derived from a hydroxyalkyl acrylate monomer,
[0096] from about 5 to about 200 repeating units of monomeric units derived from a hydrophilic monomer having a polymerizable ethylenically unsaturated reactive group, and
[0097] from about 1 to about 100 repeating units of monomeric units derived from a hydroxyalkyl acrylate monomer where the acrylate moiety is attached to the backbone of the copolymer and the hydroxy moiety is end functionalized with monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate and a polymerizable ethylenically unsaturated reactive group.
[0098] In another non-limiting illustrative embodiment, an ink binder polymer for use herein can be a silicone copolymer comprising a reaction product of (a) a copolymerization product of a polymerization composition comprising (i) an alkylacrylamide monomer, (ii) a hydroxyalkyl acrylate monomer, (iii) a non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive end group, and (iv) a bulky siloxane monomer having an ethylenically unsaturated reactive end group, with (b) a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive end group.
[0099] In some embodiments, an alkylacrylamide monomer for use in the polymerization composition includes, for example, N,N-dimethylacrylamide, N,N-dimethylmethacrylamide, and the like.
[0100] The polymerization composition can contain from about 20 wt. % to about 60 wt. %, based on the total weight of the polymerization composition, of the alkylacrylamide monomer. In some embodiments, the polymerization composition can contain from about 40 wt. % to about 45 wt. %, based on the total weight of the polymerization composition, of the alkylacrylamide monomer.
[0101] In some embodiments, a hydroxyalkyl acrylate monomer for use in the polymerization composition includes hydroxy Ci to Ce acrylate monomers. In some embodiments, a hydroxyalkyl acrylate monomer for use in the polymerization composition is represented by the following structure:
[0102] In some embodiments, the polymerization composition can contain from about 0.01 wt. % to about 40 wt. %, based on the total weight of the polymerization composition, of the hydroxyalkyl acrylate monomer. In some embodiments, the polymerization composition can contain from about 20 wt. % to about 30 wt. %, based on the total weight of the polymerization composition, of the hydroxyalkyl acrylate monomer.
[0103] The polymerization composition further includes a non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive group. An “organosilicon-containing monomer” as used herein contains at least one [siloxanyl] or at least one [silyl-alkyl-siloxanyl] repeating unit, in a monomer, macromer or prepolymer. In an illustrative embodiment, an example of a non-bulky organosilicon-containing monomer is represented by a structure of Formula la:
[0104] wherein V is an ethylenically unsaturated polymerizable group, L is a linking group or a bond; R1, R2, R3, R4, R5, R6, R7, R8, and R9are independently hydrogen, an alkyl group, a haloalkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkenyl group, a halo alkenyl group, or an aryl group; R10and R11are independently hydrogen or an alkyl group wherein at least one of R10and R11is hydrogen; y is 2 to 7 and n is 1 to 100 or from 1 to 20.
[0105] Ethylenically unsaturated polymerizable groups are well known to those skilled in the art. Suitable ethylenically unsaturated polymerizable groups include, for example, (meth)acrylates, vinyl carbonates, O-vinyl carbamates, N-vinyl carbamates, and (meth)acry lamides .
[0106] Linking groups can be any divalent radical or moiety and include, for example, a substituted or unsubstituted Ci to C12 alkyl group, an alkyl ether group, an alkenyl group, analkenyl ether group, a halo alkyl group, a substituted or unsubstituted siloxane group, and monomers capable of propagating ring opening.
[0107] In one embodiment, V is a (meth)acrylate, L is a Ci to C12 alkylene group, R1, R2, R3, R4, R5, R6, R7, R8, and R9are independently a Ci to C12 alkyl group, R10and R11are independently H or a Ci to C12 alkyl group, y is 2 to 7 and n is 3 to 8.
[0108] In one embodiment, V is a (meth)acrylate, L is a Ci to Ce alkyl group, R1, R2, R3, R4, R5, R6, R7, R8, and R9are independently a Ci to Ce alkyl group, R10and R11are independently H or a Ci to Ce alkyl group, y is 2 to 7 and n is 1 to 20.
[0109] Non-bulky organosilicon-containing monomers represented by a structure of Formula la are known in the art, see, e.g., U.S. Patent Nos. 7,915,323, 7,994,356, 8,420,711, 8,827,447 and 9,039,174, the contents of which are incorporated by reference herein.
[0110] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, an example of a non-bulky organosilicon-containing monomer is represented by a structure of Formula lb:
[0111] wherein R12is H or methyl; X is O or NR16; wherein R16is selected from H, or Ci to C4 alkyl, which may be further substituted with one or more hydroxyl groups, and in some embodiments is H or methyl; R13is a divalent alkyl group, which may further be functionalized with a group selected from the group consisting of ether groups, hydroxyl groups, carbamate groups and combinations thereof, and in another embodiment a Ci to Ce alkylene group which may be substituted with ether, hydroxyl and combinations thereof, and in yet another embodiment a Ci or C3 to C4 alkylene group which may be substituted with ether, hydroxyl and combinations thereof; each R14is independently a phenyl or a Ci to C4 alkyl group which may be substituted with fluorine, hydroxyl or ether, and in another embodiment each R14is independently selected from ethyl and methyl groups, and in yet another embodiment, each R14is methyl; R15is a Ci to C4 alkyl group; a is 2 to 50, and in some embodiments 5 to 15.
[0112] Non-bulky organosilicon-containing monomers represented by a structure of Formula lb are known in the art, see, e.g., U.S. Patent Nos. 8,703,891, 8,937,110, 8,937,111, 9,156,934 and 9,244,197, the contents of which are incorporated by reference herein.
[0113] Representative examples of non-bulky organosilicon-containing monomers for use herein include:
[0114] M1EDS6-TMS: a compound having the structure and available from Gelest:
[0115] MCR-M11 : a compound having the structure:
[0116] M1-MCR-C12: a compound having the structure:wherein n is an average of 12.
[0117] The polymerization composition can contain from about 0.10 wt. % to about 30 wt. %, based on the total weight of the polymerization composition, of a non-bulky organosilicon- containing monomer. In some embodiments, the polymerization composition can contain from about 5 wt. % to about 15 wt. %, based on the total weight of the polymerization composition, of a non-bulky organosilicon-containing monomer.
[0118] The polymerization composition further includes a bulky siloxane monomer having an ethylenically unsaturated reactive group. The term “bulky” refers to groups on the siloxane monomer that are sterically and / or electronically encumbering, i.e., sterically hindering. In a nonlimiting illustrative embodiment, suitable bulky siloxane monomers include, for example, a bulky polysiloxanylalkyl (meth)acrylic monomer, a bulky polysiloxanylalkyl carbamate monomer and mixtures thereof. In one embodiment, a representative example of a bulky siloxane monomer is represented by a structure of Formula II:
[0119] wherein X denotes -O- or -NR19-, where each R19is hydrogen or a C1-C4 alkyl group; R17independently denotes hydrogen or methyl; each R18independently denotes a lower alkyl radical such as a Ci-Ce group, a phenyl radical or a group represented by the following structure:R18— Si— R18X18'
[0120] wherein each R18independently denotes a lower alkyl radical such as a Ci-Ce group or a phenyl radical; and h is 1 to 10; or is represented by a structure of Formula III:R18R1— Si — R18
[0121] wherein X denotes -NR19- wherein R19denotes hydrogen or a C1-C4 alkyl; R17denotes hydrogen or methyl; each R18independently denotes a lower alkyl radical such as a Ci-Ce group, a phenyl radical or a group represented by the following structure:R18— Si— R18X18'
[0122] wherein each R18' independently denotes a lower alkyl radical such as a Ci-Ce group or a phenyl radical; and h is 1 to 10.
[0123] Representative examples of bulky siloxane monomers include 3-methacryloyloxypropyltris(trimethylsiloxy)silane or tris(trimethylsiloxy)silylpropyl methacrylate, sometimes referred to as TRIS and tris(trimethylsiloxy)silylpropyl vinyl carbamate, sometimes referred to as TRIS-VC, pentamethyldisiloxanyl methylmethacrylate, phenyltetramethyl-disiloxanylethyl acetate, and methyldi(trimethylsiloxy)methacryloxymethyl silane, (3-methacryloxy-2 -hydroxy propoxy)propyl bis(trimethyl siloxy)methyl silane, sometimes referred to as Sigma and the like and mixtures thereof. In one embodiment, the bulky siloxane monomer is a tris(trialkylsiloxy)silylalkyl methacrylate-containing monomer such as a tris(trimethylsiloxy)silylpropyl methacrylate-containing monomer.
[0124] Such bulky monomers may be copolymerized with a silicone macromonomer, which is a poly(organosiloxane) capped with an unsaturated group at two or more ends of the molecule. U.S. Patent No. 4,153,641 discloses, for example, various unsaturated groups such as acryloxy or methacryloxy groups.
[0125] The polymerization composition can contain from about 5 wt. % to about 30 wt. %, based on the total weight of the polymerization composition, of a bulky organosilicon-containing monomer. In some embodiments, the polymerization composition can contain from about 15 wt. % to about 25 wt. %, based on the total weight of the polymerization composition, of a bulky organosilicon-containing monomer.
[0126] In non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the polymerization composition can further include an ultraviolet (UV) blocker having an ethylenically unsaturated reactive group. Suitable UV blockers having an ethylenically unsaturated reactive group can be any known UV blocker having an ethylenically unsaturated reactive group. In some embodiments, a UV blocker for use herein can include a phenolic group having a hydroxyl moiety and one or more ethylenically unsaturated reactive groups. In a non-limiting illustrative embodiment, a UV blocker comprising a phenolic group having a protected hydroxyl moiety and one or more ethylenically unsaturated reactive groups can be represented by a benzotriazole compound having a structure of Formula IV:wherein each R is independently hydrogen, a halogen, an -O- group, a nitro group, a nitrile group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted hydroxyl group, a substituted or unsubstituted amine group, a substituted or unsubstituted carbonyl group, and a substituted or unsubstituted hydrocarbyl group, R* is hydrogen or a substituted or unsubstituted hydrocarbyl group, and R** is an ethylenically unsaturated reactive group.
[0127] As used herein, recitations of “substituted” group, means a group such as an alkyl group, cycloalkyl group, heterocycloalkyl group, aryl group, and / or heteroaryl group, in which at least one hydrogen atom thereof has been optionally replaced or substituted with a group that is other than hydrogen, such as, for example, halo groups (e.g., F, Cl, I, and Br), hydroxyl groups, ether groups, thiol groups, thio ether groups, carboxylic acid groups, carboxylic acid ester groups,phosphoric acid groups, phosphoric acid ester groups, sulfonic acid groups, sulfonic acid ester groups, nitro groups, cyano groups, hydrocarbyl groups (e.g., alkyl; alkenyl; alkynyl; cycloalkyl, including poly-fused-ring cycloalkyl and polycyclocalkyl; heterocycloalkyl; aryl, including hydroxyl substituted aryl, such as phenol, and including poly-fused-ring aryl; heteroaryl, including poly-fused-ring heteroaryl; and aralkyl groups), and amine groups.
[0128] As used herein, recitations of “linear or branched” groups, such as linear or branched alkyl, are herein understood to include, for example, groups that are linear, such as linear C2 to C30 alkyl groups; and groups that are appropriately branched, such as branched C3 to C30 alkyl groups.
[0129] Representative examples of halogen groups include, by way of example, Cl, I, F, and Br.
[0130] Representative examples of hydrocarbyl groups include linear or branched alkyl groups, linear or branched alkenyl groups, linear or branched alkynyl groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups (including polycyclic aryl groups), heteroaryl groups (having at least one hetero atom in the aromatic ring); and aralkyl groups as defined herein.
[0131] Representative examples of alkoxy groups for use herein include, by way of example, an alkyl group as defined herein attached via oxygen linkage to the rest of the molecule, i.e., of the general formula -OR1, wherein R1is an alkyl, cycloalkyl, or aromatic group as defined herein, e.g., -OCH3, -OC2H5, or -OCeHs which may be substituted or unsubstituted, and the like.
[0132] Representative examples of alkenyl groups for use herein include, by way of example, a straight or branched hydrocarbon chain radical containing from about 3 to about 30 carbon atoms with at least one carbon-carbon double bond such as, for example, propenyl, butenyl, pentenyl and the like.
[0133] Representative examples of alkynyl groups for use herein include, by way of example, a straight or branched hydrocarbon chain radical containing from about 3 to about 30 carbon atoms with at least one carbon-carbon triple bond such as, for example, propynyl, butynyl, pentynyl and the like.
[0134] Representative examples of aralkyl groups as used herein, and in accordance with some embodiments, include, but are not limited to, Ce to C24 aralkyl, such as a Ce to C10 aralkyl, and means an aryl group substituted with an alkyl group.
[0135] Representative examples of amine groups for use herein include, by way of example, an amine of the general formula -R2NR3R4wherein R2, R3and R4are independently hydrogen or a C1-C30 hydrocarbon such as, for example, alkyl groups, aromatic groups, or cycloalkyl groups as defined herein, and the like.
[0136] The term “carbonyl group” as used herein is a divalent group of the formula -C(=O).
[0137] In an illustrative embodiment, R and R* are each hydrogen and R** is a (meth)acrylate-containing reactive end group.
[0138] In another illustrative embodiment, as may be combined with one or more of the preceding paragraphs, R** is positioned on the aromatic ring in the para position relative to the OH moiety.
[0139] Representative examples of suitable UV blockers include 2-(2’ -hydroxy-3 methallyl-5’-methylphenyl)benzotriazole, commercially available as o-Methallyl Tinuvin P (“oMTP”) from Polysciences, Inc., Warrington, Pa., 3-(2H-benzo[d][l,2,3]triazol-2-yl)-4-hydroxyphenylethyl methacrylate, and 2-(3-(tert-butyl)-4-hydroxy-5-(5 -methoxy -2H-benzo[d][l,2,3]triazol-2-yl)phenoxy)ethyl methacrylate.
[0140] In one illustrative embodiment, suitable UV blockers include, for example, one or more compounds of the following formulae:(2-Propenoic acid, 2-methyl,2-(4-benzoyl-3-hydroxyphenoxy)-l -[(4-benzoyl3-hydroxyphenoxy)methyl ester),HOOH OO
[0141] The foregoing UV blockers are merely illustrative and not intended to be limiting. Any known UV blocker comprising a phenolic group having a hydroxyl moiety and one or more ethylenically unsaturated reactive groups or later developed UV blocker comprising a phenolic group having a hydroxyl moiety and one or more ethylenically unsaturated reactive groups are contemplated for use herein.
[0142] The foregoing UV blockers for use herein are known and either commercially available from such sources as, for example, Aldrich, Polysciences, Gelest, and Melrob, or can be made by methods within the purview of one skilled in the art.
[0143] The polymerization composition can contain from about 0.1 wt. % to about 5 wt. %, based on the total weight of the polymerization composition, of a UV blocker. In some embodiments, the polymerization composition can contain from about 0.5 wt. % to about 1.5 wt. %, based on the total weight of the polymerization composition, of a UV blocker.
[0144] In non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the polymerization composition can further include one or more bluelight blockers having an ethylenically unsaturated reactive group. Many reactive blue-light absorbing compounds are known, see, e.g., the reactive blue-light absorbing compounds described in U.S. Pat. Nos. 5,470,932; 8,207,244; and 8,329,775, the contents of which are hereby incorporated by reference.
[0145] In non-limiting illustrative embodiments, a class of blue light blockers can include a phenolic group comprising a hydroxyl moiety and one or more ethylenically unsaturated reactive groups represented by an acridone compound having a structure of Formula V:wherein R* and R** are as defined above.
[0146] In an illustrative embodiment, R* is hydrogen and R** is a (meth)acrylate-containing reactive end group as defined above.
[0147] In some embodiments, R** is positioned on the aromatic ring in the para position relative to the OH moiety.
[0148] The foregoing one or more blue light blockers comprising a phenolic group having a hydroxyl moiety and one or more ethylenically unsaturated reactive groups are merely illustrative and not intended to be limiting. Any known blue light blockers comprising a phenolic group having a hydroxyl moiety and one or more ethylenically unsaturated reactive groups or later developed blue light blockers comprising a phenolic group having a hydroxyl moiety and one or more ethylenically unsaturated reactive groups are contemplated for use herein.
[0149] In some embodiments, a blue-light blocker is N-2-[3-(2’-methylphenylazo)-4-hydroxyphenyl] ethyl methacrylamide.
[0150] The foregoing blue light blockers for use herein are known and either commercially available from such sources as, for example, Vishwa-Syntharo PharmaCompany, or can be made by methods within the purview of one skilled in the art.
[0151] The blue-light absorbers can be present in the polymerization composition in an amount ranging from about 0.005 wt. % to about 1 wt. %, based on the total weight of the polymerization composition. In some embodiments, the blue-light absorbers can be present in the polymerization composition in an amount ranging from about 0.01 wt. % to about 1 wt. %, based on the total weight of the polymerization composition.
[0152] A copolymerization product of a polymerization composition comprising (i) an alkylacrylamide monomer, (ii) a hydroxyalkyl acrylate monomer, (iii) a non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive group, and (iv) a bulky siloxanemonomer having an ethylenically unsaturated reactive group, and optionally (v) an ultraviolet blocker having an ethylenically unsaturated reactive group and / or (vi) a blue-light blocker having an ethylenically unsaturated reactive group can be prepared using free radical polymerization techniques with the structure of the polymer being completely random or controlled by the reactivity ratios of the respective monomers.
[0153] In some embodiments, a random copolymer can be obtained by (1) mixing the components to obtain a polymerization composition, (2) adding a polymerization initiator to the polymerization composition, and (3) subjecting the monomer / initiator mixture to a source of heat or radiation such as ultraviolet light, visible light, or high energy radiation to obtain a copolymerization product as discussed below. Suitable free radical thermal polymerization initiators include acetyl peroxide, lauroyl peroxide, decanoyl peroxide, coprylyl peroxide, benzoyl peroxide, tertiary butyl peroxypivalate, sodium percarbonate, tertiary butyl peroctoate, and azobis-isobutyronitrile (AIBN), and the like. Representative UV initiators are those known in the art and include benzoin methyl ether, benzoin ethyl ether, Darocure® 1173, 1164, 2273, 1116, 2959, 3331 (EM Industries) and Irgacure® 651 and 184 (Ciba-Geigy), 2,2’Azobis(2-methylpropionitrile) (Vazo 64) and the like. Generally, the initiator will be employed in the mixture at a concentration of about 0.01 to about 5 percent by weight of the total mixture.
[0154] Suitable polymerization conditions include, for example, a temperature of between about 60°C to about 100°C for a time period of about 30 minutes to about 48 hours. If desired, the reaction can be carried out in the presence of a suitable solvent. Suitable solvents are in principle all solvents which dissolve the monomers used including, for example, 1,4-di oxane, hexanol, dimethylformamide; acetone, cyclohexanone, toluene, and the like and mixtures thereof.
[0155] The copolymerization product disclosed herein can also be prepared using techniques of controlled radical polymerization, e.g., by reversible addition-fragmentation chain transfer (RAFT) polymerization or atom-transfer radical polymerization (ATRP) employing a chain transfer agent that allows construction of copolymers with a well-defined molecular weight distribution and narrow polydispersity as discussed above.
[0156] In an illustrative embodiment, the RAFT procedure is carried using a mixture including (i) from about 2 wt. % to about 40 wt. %, based on the total weight of the mixture, of an alkylacrylamide monomer, (ii) from about 10 wt. % to about 20 wt. %, based on the total weightof the mixture, of a hydroxyalkyl acrylate monomer, (iii) from about 10 wt. % to about 60 wt. %, based on the total weight of the mixture, of a non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive group, and (iv) from about 20 wt. % to about 60 wt. %, based on the total weight of the mixture, of a bulky siloxane monomer having an ethylenically unsaturated reactive group, and (v) from about 0.05 wt. % to about 2 wt. %, based on the total weight of the mixture, of the RAFT agent. The level of initiator employed will vary within the range of 0.01 wt. % to 2 wt. % of the mixture of monomers. In some embodiments, the mixture for the RAFT procedure further includes from about 0.1 wt. % to about 5 wt. %, based on the total weight of the mixture, of an ultraviolet blocker having an ethylenically unsaturated reactive group.
[0157] A non-limiting schematic representation of a synthetic method for making a copolymerization product with a RAFT agent is set forth below in Scheme II below.Scheme IIo
[0158] In the case where the copolymerization product disclosed herein is obtained from ATRP polymerization, the copolymerization product is obtained from ATRP polymerization by (1) mixing an alkylacrylamide monomer, a hydroxyalkyl acrylate monomer, a non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive group, a bulky siloxane monomer having an ethylenically unsaturated reactive group, and optionally an ultraviolet blocker having an ethylenically unsaturated reactive group and / or a blue-light blocker having an ethylenically unsaturated reactive group with, for example, an ATRP initiator and suitable ATRPcatalyst such as a copper(I) bromide and (2) subjecting the monomer / ATRP agent / initiator mixture to a source of heat.
[0159] The reaction can be carried out at a temperature of between about 60°C to about 100°C for a time period of about 30 minutes to about 48 hours. If desired, the reaction can be carried out in the presence of a suitable solvent. Suitable solvents are in principle all solvents which dissolve the monomer used, for example, 1,4-di oxane, hexanol, dimethylformamide; acetone, cyclohexanone, toluene, and the like and mixtures thereof.
[0160] In an illustrative embodiment, the ATRP procedure is carried using a mixture including (i) from about 0.1 wt. % to about 20 wt. %, based on the total weight of the mixture, of an alkylacrylamide monomer, (ii) from about 5 wt. % to about 20 wt. %, based on the total weight of the mixture, of a hydroxyalkyl acrylate monomer, (iii) from about 10 wt. % to about 20 wt. %, based on the total weight of the mixture, of a non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive group, (iv) from about 20 wt. % to about 60 wt. %, based on the total weight of the mixture, of a bulky siloxane monomer having an ethylenically unsaturated reactive group, and (v) from about 0.05 wt. % to about 5 wt. %, based on the total weight of the mixture, of the ATRP initiator. The level of catalyst employed will vary within the range of 0.01 wt. % to 2 wt. % of the mixture of monomers. In some embodiments, the mixture for the ATRP procedure further includes from about 20 wt. % to about 40 wt. %, based on the total weight of the mixture, of an ultraviolet blocker having an ethylenically unsaturated reactive group.
[0161] As one skilled in the art will readily appreciate, the copolymerization product disclosed herein can contain a balance of monomeric units derived from an alkylacrylamide monomer, monomeric units derived from a hydroxyalkyl acrylate monomer, monomeric units derived from a non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive group, monomeric units derived from a bulky siloxane monomer having an ethylenically unsaturated reactive group, and optionally monomeric units derived from an ultraviolet blocker having an ethylenically unsaturated reactive group.
[0162] In some embodiments, a copolymerization product can include from about 50 to about 400 repeating units of monomeric units derived from an alkylacrylamide monomer, from about 50 to about 200 repeating units of monomeric units derived from a hydroxyalkyl acrylate monomer, from about 20 to about 300 repeating units of monomeric units derived from a non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive group, from about 1 to about 400 repeating units of monomeric units derived from the bulky siloxane monomer having an ethylenically unsaturated reactive end group, and optionally from about 1 to about 25 repeating units of monomeric units derived from an ultraviolet blocker having an ethylenically unsaturated reactive group.
[0163] In some embodiments, the copolymerization product is thereafter reacted with a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive group to obtain a silicone prepolymer. The foregoing reaction will result in additional monomeric units derived from the hydroxyalkyl acrylate monomer with the hydroxy moiety being reacted with the reactive functionality of the monomer such that the hydroxyalkyl acrylate monomer contains an end functionalized group, i.e., a polymerizable ethylenically unsaturated reactive group. Suitable polymerizable ethylenically unsaturated reactive groups can be any of those discussed above.
[0164] In an illustrative embodiment, a polymerizable ethylenically unsaturated reactive group can be one or more of an acrylate end group and a methacrylate end group.
[0165] A suitable monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive group include, for example, 2-isocyanatoethyl acrylate, 3-isocyanatopropyl acrylate, 2-isocyanatoethyl methacrylate, 1 -methyl-2-isocyanatoethyl methacrylate, 1,1-dimethy 1-2-isocyanatoethyl acrylate, (meth)acryloyl chloride, vinyl chloroformate and the like.
[0166] The copolymerization product is present in the reaction mixture in an amount ranging from about 10 wt. % to about 90 wt. %, based on the total weight of the reaction mixture. In an illustrative embodiment, the copolymerization product is present in the reaction mixture in an amount ranging from about 50 wt. % to about 80 wt. %, based on the total weight of the reaction mixture.
[0167] In an illustrative embodiment, the monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate and a polymerizable ethylenically unsaturated reactive group is present in the reaction mixture in an amount ranging from about 5 wt. % to about 60 wt. %, based on the total weight of the reaction mixture. In an illustrative embodiment, the monomer having a reactive functionality complementary to one of theone or more reactive functionalities of the hydrophilic monomer and a polymerizable ethylenically unsaturated reactive group is present in the reaction mixture in an amount ranging from about 10 wt. % to about 20 wt. %, based on the total weight of the reaction mixture.
[0168] The reaction of the copolymerization product and the monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate and a polymerizable ethylenically unsaturated reactive group can be carried out in the presence of a catalyst as discussed above. The amount of catalyst employed is generally between about 0.01 wt. % to about 5 wt. % of the mixture catalyzed.
[0169] The reaction can be carried out at a temperature of between about 60°C to about 100°C for about 2 hours to about 24 hours. The reaction can be carried out in the presence of a suitable solvent as discussed above.
[0170] Accordingly, in a non-limiting illustrative embodiment, a silicone prepolymer disclosed herein comprises:
[0171] (i) monomeric units derived from an alkylacrylamide monomer,
[0172] (ii) monomeric units derived from a hydroxyalkyl acrylate monomer,
[0173] (iii) monomeric units derived from a hydroxyalkyl acrylate monomer where the acrylate moiety is attached to the backbone of the copolymer and the hydroxy moiety is end functionalized with monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate and a polymerizable ethylenically unsaturated reactive group,
[0174] (iv) monomeric units derived from a bulky siloxane monomer,
[0175] (v) monomeric units derived from a non-bulky siloxane monomer, and
[0176] optionally (vi) monomeric units derived from an ultraviolet blocker having one or more reactive functionalities.
[0177] In some embodiments, a silicone prepolymer is a silicone random copolymer.
[0178] In some embodiments, a silicone prepolymer disclosed herein includes:
[0179] from about 50 to about 400 repeating units of monomeric units derived from an alkylacrylamide monomer,
[0180] from about 50 to about 200 repeating units of monomeric units derived from a hydroxyalkyl acrylate monomer,
[0181] from about 5 to about 20 repeating units of monomeric units derived from a hydroxyalkyl acrylate monomer where the acrylate moiety is attached to the backbone of the copolymer and the hydroxy moiety is end functionalized with monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate and a polymerizable ethylenically unsaturated reactive group,
[0182] from about 20 to about 300 repeating units of monomeric units derived from a non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive group, and
[0183] from about 1 to about 400 repeating units of monomeric units derived from a bulky siloxane monomer having an ethylenically unsaturated reactive group.
[0184] In non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, a silicone prepolymer disclosed herein further includes from about 1 to about 25 repeating units of monomeric units derived from an ultraviolet blocker having an ethylenically unsaturated reactive group.
[0185] In some embodiments, a silicone prepolymer disclosed herein can have a weight average molecular weight ranging from about 2,000 to about 300,000 Daltons. The weight average molecular weight of the silicone prepolymer is determined by Gel Permeation Chromatography (GPC).
[0186] 3, Lifitegrast or Salt Thereof
[0187] In some embodiments, a lifitegrast-containing ink binder of the present disclosure includes one or more of a lifitegrast or a salt thereof, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group and a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group. In general, lifitegrast is represented by the following structure:OOand a salt of lifitegrast is represented by the following structure:\\owhere x is a salt such as a sodium salt.
[0188] In some embodiments, a lifitegrast or a salt thereof-containing monomer or lifitegrast or salt thereof-containing polymer may have one or more releasable linking groups. In some embodiments, a releasable linking group refers to a linking group that includes at least one bond that can be broken under physiological conditions. For example, a releasable linking group can include where the releasable linking group is a group linking the lifitegrast or salt thereof to a monomer comprising an ethylenically unsaturated reactive group or to a polymer optionally comprising an ethylenically unsaturated reactive group via a pH-labile bond, an acid-labile bond, a base-labile bond, an oxidatively labile bond, a metabolically labile bond, a biochemically labile bond or an enzyme-labile bond, or other conditions such as a standard chemical reaction via a chemical-labile bond, e.g., a hydrolysis or substitution reaction, or via a photo-labile bond, e.g., exposure to light such as UV, near UV or visible light, e.g., a photosensitive bond. If the releasable linking groups are naturally cleaved under physiological conditions or cellular physiological conditions, then the monomer or polymer is biodegradable. In some embodiments, the releasable linking groups results in a loss of the lifitegrast or salt thereof from side chain atom of the lifitegrast or salt thereof-containing monomer or lifitegrast or salt thereof-containing polymer thereby releasing the lifitegrast or salt thereof.
[0189] In some embodiments, the releasable linking group includes ester groups. In the case of ester bonds, the esters undergo hydrolysis and are also catalytically cleaved by esterases thereby releasing the lifitegrast or salt thereof. Representative examples of a lifitegrast or a salt thereof-containing monomer having an ester linking group include those having the following structures:o
[0190] In some embodiments, the releasable linking group includes a photocleavable linking group. Suitable photocleavable linking groups include, for example, a nitrobenzyl group, phenacyl group, pyronin group, benzoin group and coumarin group. In one aspect, the photocleavable linking group has at least two reactive groups. The first reactive group allows linking of the photocleavable linking group to one of the polymer backbone of the copolymerization product or to a reactive group of the polymer utilized in forming the lifitegrast or salt thereof-containing polymer, e.g., a glycosaminoglycan (GAG) polymer as discussed below. The second reactive group allows linking of the photocleavable linking group to a reactive group of the lifitegrast or salt thereof. The former handle is preferably stable, and the latter handle is preferably amenable to photolysis such that the lifitegrast or salt thereof is released from the photocleavable lifitegrast conjugate upon exposure to light of the appropriate wavelength. The photocleavable group therefore breaks its bond with the lifitegrast or salt thereof, removing the charged groups from the lifitegrast or salt thereof. The lifitegrast or salt thereof is then in its native form with no additions.
[0191] Representative examples of a lifitegrast or a salt thereof-containing monomer having a photocleavable linking group includes those having the following structure:
[0192] In some embodiments, a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group can include, for example, a lifitegrast or a salt thereof-containing GAG polymer comprising a GAG having a polymer backbone and a first side chain a lifitegrast or a salt thereof residue grafted onto the polymer backbone, and optionally a second side chain comprising an ethylenically unsaturated reactive-containing residue grafted onto the polymer backbone.
[0193] A GAG is one molecule with many alternating subunits. In general, GAGs are represented by the formula A-B-A-B-A-B, where A is uronic acid and B is an amino sugar that may or may not be either O- or N-sulfated, where the A and B units can be heterogeneous with respect to epimeric content or sulfation. Any natural or synthetic polymer containing uronic acid can be used. Other GAGs are sulfated at different sugars. There are many different types of GAGs having commonly understood structures such as, for example, chondroitin sulfate (e.g., chondroitin 4- and 6- sulfates), heparan, heparin sulfate, heparosan, dermatan, dermatan sulfate, hyaluronic acid or a salt thereof, e.g., sodium hyaluronate or potassium hyaluronate, keratan sulfate, and other disaccharides such as sucrose, lactulose, lactose, maltose, trehalose, cellobiose, mannobiose and chitobiose. GAGs can be purchased from Sigma, and many other biochemical suppliers such as HTL Biotechnology (France). In an illustrative embodiment, the GAG is hyaluronic acid. In another illustrative embodiment, the GAG is chondroitin sulfate.
[0194] In an illustrative embodiment, a GAG for use herein can have a weight average molecular weight ranging from about 10,000 to about 3,000,000 Daltons (Da) in which the lowerlimit is from about 10,000, about 20,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, or about 100,000 Da, and the upper limit is about 200,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, or about up to 2,800,000 Da, where any of the lower limits can be combined with any of the upper limits. In an illustrative embodiment, a GAG for use herein can have a weight average molecular weight ranging from about 1,000,000 to about 3,000,000 Da.
[0195] Hyaluronic acid is a well-known, naturally occurring, water soluble biodegradable polymer composed of two alternatively linked sugars, D-glucuronic acid and N-acetylglucosamine, linked via alternating 0-(l,4) and 0-(l,3) glycosidic bonds. Hyaluronic acid is a non-sulfated GAG. The polymer is hydrophilic and highly viscous in aqueous solution at relatively low solute concentrations. It often occurs naturally as the sodium salt, sodium hyaluronate. Methods of preparing commercially available hyaluronan and salts thereof are well known. Hyaluronan can be purchased from Seikagaku Company, Clear Solutions Biotech, Inc., Pharmacia Inc., Sigma Inc., HTL Biotechnology, Contipro and Bloomage Biotechnology Corporation, and many other suppliers. Hyaluronic acid has repeating units of the structure represented by the following formula:Accordingly, the repeating units in hyaluronic acid can be as follows:P-D-Glucuronic acid N-Acetyl-P-D-Glucosamine P-D-Glucuronic acid N-Acetyl-P-D- Glucosamine
[0196] In general, hyaluronic acid or a salt thereof can have from about 2 to about 1,500,000 disaccharide units. In an embodiment, hyaluronic acid or a salt thereof can have aweight average molecular weight ranging from about 10,000 to about 3,000,000 Da in which the lower limit is from about 10,000, about 20,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, or about 100,000 Da, and the upper limit is about 200,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, or about up to 2,800,000 Da, where any of the lower limits can be combined with any of the upper limits.
[0197] Chondroitin sulfate is a linear sulfated polysaccharide composed of repeating 0- D-glucuronic acid (GlcA) and N-acetyl-0-D-galactosamine (GalNAc) units arranged in the sequence by GlcA- 0(l,3)-GalNAc- 0(1,4) glycosidic bonds. In an embodiment, chondroitin sulfate has one or more repeating units of the structure represented by the following formula:
[0198] In an illustrative embodiment, chondroitin sulfate has repeating units of the structure represented by the following formula:OHO=S=OI
[0199] In general, chondroitin sulfate can have from about 2 to about 1,500,000 repeating units. In an embodiment, chondroitin sulfate can have a weight average molecular weight ranging from about 10,000 to about 3,000,000 Da in which the lower limit is from about 5,000, 10,000, about 20,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, or about 100,000 Da, and the upper limit is about 200,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about1,000,000, or about 3,000,000 Da where any of the lower limits can be combined with any of the upper limits or any of the upper limits can be combined with any of the upper limits.
[0200] In an illustrative embodiment, dermatan sulfate has repeating units of the structure represented by the following formula:
[0201] In general, dermatan sulfate can have from about 2 to about 1,500,000 repeating units. In an embodiment, dermatan sulfate can have a weight average molecular weight ranging from about 1,000 to about 2,000,000 Da in which the lower limit is from about 1,000, 5,000, 10,000, about 20,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, or about 100,000 Da, and the upper limit is about 200,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, or about 2,000,000 Da where any of the lower limits can be combined with any of the upper limits or any of the upper limits can be combined with any of the upper limits.
[0202] In an illustrative embodiment, heparin and heparin sulfate has repeating units of the structure represented by the following formula:O I I
[0203] In general, heparin and heparin sulfate can have from about 2 to about 1,500,000 repeating units. In an embodiment, heparin and heparin sulfate can have a weight average molecular weight ranging from about 1,000 to about 3,000,000 Da in which the lower limit is from about 1,000, 5,000, 10,000, about 20,000, about 30,000, about 40,000, about 50,000, about 60,000,about 70,000, about 80,000, about 90,000, or about 100,000 Da, and the upper limit is about 40,000, 100,000, 200,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, or about 3,000,000 Da where any of the lower limits can be combined with any of the upper limits or any of the upper limits can be combined with any of the upper limits.
[0204] In an illustrative embodiment, keratan sulfate has repeating units of the structure represented by the following formula:
[0205] In general, keratan sulfate can have from about 2 to about 1,500,000 repeating units. In an embodiment, keratan sulfate can have a weight average molecular weight ranging from about 10,000 to about 3,000,000 Da in which the lower limit is from about 5,000, 10,000, about 20,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, or about 100,000 Da, and the upper limit is about 100,000, 200,000, about 300,000, about 400,000, about 500,000, about 550,000, 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, or about 3,000,000 Da where any of the lower limits can be combined with any of the upper limits or any of the upper limits can be combined with any of the upper limits.
[0206] A representative example of a reaction scheme to form a lifitegrast or a salt thereof-containing hyaluronic acid polymer can be seen below in Scheme III.Scheme III
[0207] A representative example of a reaction scheme to form a lifitegrast or a salt thereof-containing hyaluronic acid polymer with a releasable linking group can be seen below in Scheme IV.Scheme IV
[0208] In some embodiments, a lifitegrast or a salt thereof-containing polymer can contain an ethylenically unsaturated reactive group. For example, the lifitegrast or salt thereof-containing polymer can include an ethylenically unsaturated reactive-containing residue grafted onto a reactive functional group in the polymer backbone of the GAG. The ethylenically unsaturated reactive-containing residue can be derived from a monomer comprising an ethylenicallyunsaturated reactive group and at least one reactive end group. In one embodiment, the ethylenically unsaturated reactive-containing residue is a methacrylate-containing residue. The at least one reactive end group includes a reactive functional group capable of grafting on to a complementary reactive functional group in the polymer backbone of the GAG. Suitable reactive functional groups of the monomer comprising an ethylenically unsaturated reactive group and at least one reactive end group include, for example, a halogen, an anhydride, an amino group, an aldehyde group, a carboxylic acid group, an alcohol group, a thiol group, a hydrazide group, a glycidyl group, etc. In one non-limiting illustrative embodiment, an ethylenically unsaturated reactive-containing residue can be derived from, for example, methacrylic anhydride, methacryloyl chloride, 2-isocyanoethylmethacrylate, 3 -(trimethoxy silyl)propyl methacrylate, 3-(chlorodimethylsilyl)propyl methacrylate, glycidyl methacrylate, methacryloyl hydrazide, aminoethyl methacrylate, vinyl chloroformate, allyl chloride, acryloyl chloride, and acrylic anhydride. However, other monomers for forming the ethylenically unsaturated reactivecontaining residue on the polymer backbone of the GAG are contemplated and the foregoing list is merely exemplary.
[0209] The lifitegrast or salt thereof-containing GAG polymers disclosed herein can be obtained by grafting the at least one reactive end group of the one or more monomers comprising an ethylenically unsaturated reactive group onto a complementary reactive functionality in the polymer backbone of the GAG and grafting a reactive end group of the releasable linking group of the lifitegrast or salt thereof onto another complementary reactive functionality in the polymer backbone of the GAG. For example, in one illustrative embodiment, an anhydride group of the one or more monomers comprising an ethylenically unsaturated reactive group can be grafted onto a carboxylic acid group in the polymer backbone of the GAG. In non-limiting illustrative embodiments, the graft polymerization reaction can obtain a degree of grafting, i.e., the number of sidechains in the polymer backbone containing the ethylenically unsaturated reactive-containing residue, ranging from about 0.5 to about 50 %. In another illustrative embodiment, the degree of grafting can range from about 2 to about 30 %. In another illustrative embodiment, the degree of grafting can range from about 5 to about 20 %. In yet another illustrative embodiment, the degree of grafting can range from about 5 to about 15 %. In yet another illustrative embodiment, the degree of grafting can range from about 5 to about 10 %.
[0210] In general, the GAG, monomer comprising an ethylenically unsaturated reactive group and at least one reactive end group and the lifitegrast or salt thereof comprising a releasable linking group having a reactive end group can be added sequentially or simultaneously to a reaction mixture. The reaction can be carried out at a suitable temperature and for a time period for the completion of the reaction to maximize the yield of the product ethylenically unsaturated reactivecontaining residue grafted onto the polymer backbone of the GAG. For example, a suitable temperature and time period includes a temperature ranging from about 10°C to about 40°C and a time period ranging from about 4 hours to about 48 hours. In an illustrative embodiment, a suitable temperature and time period includes a temperature ranging from about 15°C to about 25°C and a time period ranging from about 8 hours to about 24 hours.
[0211] The GAG can be added to the reaction mixture in an amount ranging from about 0.5 wt. % to about 5 wt. %, based on the total weight of the reaction mixture. In one illustrative embodiment, a GAG can be added to the reaction mixture in an amount ranging from about 1 wt. % to about 3 wt. %, based on the total weight of the reaction mixture.
[0212] In an illustrative embodiment, a monomer comprising an ethylenically unsaturated reactive group and at least one reactive end group can be added to the reaction mixture in an amount ranging from about 0.1 wt. % to about 5 wt. %, based on the total weight of the reaction mixture. In one illustrative embodiment, a monomer comprising an ethylenically unsaturated reactive group and at least one reactive end group can be added to the reaction mixture in an amount ranging from about 0.5 wt. % to about 2 wt. %, based on the total weight of the reaction mixture.
[0213] In a non-limiting illustrative embodiment, the ethylenically unsaturated reactivecontaining residue is a methacrylate-containing residue derived from a methacrylate-containing monomer as described above, and the degree of methacrylation can range from about 0.5 to about 50 %. In another illustrative embodiment, the degree of methacrylation can range from about 2 to about 30 %. In yet another illustrative embodiment, the degree of methacrylation can range from about 5 to about 15 %.
[0214] The lifitegrast or salt thereof-containing GAG polymer can be a random copolymer or a block copolymer. In one illustrative embodiment, a lifitegrast or a salt thereof-containing polymer disclosed herein can have a weight average molecular weight ranging from about 20,000to about 6,000,000 Da in which the lower limit is from about 20,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, or about 100,000 Da, and the upper limit is about 100,000, about 150,000, about 200,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, about 2,000,000, about 3,000,000, about 4,000,000, about 5,000,000 or up to about 6,000,000 Da, wherein any of the lower limits can be combined with any of the upper limits.
[0215] A representative example of a lifitegrast or a salt thereof-containing GAG polymer comprising a releasable linking group and an ethylenically unsaturated reactive group is illustrated below:
[0216] In some embodiments, a lifitegrast or a salt thereof-containing GAG polymer comprising a GAG having a polymer backbone and a first side chain comprising a lifitegrast or a salt thereof residue comprising the releasable linking group grafted onto the polymer backbone, and a second side chain comprising an ethylenically unsaturated reactive-containing residue grafted onto the polymer backbone such as a lifitegrast or a salt thereof-containing hyaluronic acid polymer can be made by a reaction scheme seen below in Scheme V.Scheme V
[0217] A representative example of a reaction scheme to form a lifitegrast or a salt thereof-containing hyaluronic acid polymer with a releasable linking group can be seen below in Scheme VI.Scheme VI
[0218] A representative example of a reaction scheme to form a lifitegrast or a salt thereof-containing hyaluronic acid polymer with a releasable linking group that is a photocleavable can be seen below in steps 1 and 2 of Scheme VII.Scheme VIIStep 1
[0219] In some embodiments, a lifitegrast-containing ink binder of the present disclosure includes a solvent in an amount of from about 10 wt. % to about 60 wt. %, or from about 20 wt. % to about 25 wt. %; an ink binder polymer in an amount of from about 5 wt. % to about 40 wt. %, or from about 10 wt. % to about 25 wt. %, based on the total weight of the lifitegrast-containing ink binder, and one or more of a lifitegrast or a salt thereof, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group and a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group in an amount of from about 1 wt. % to about 30 wt. %, or from about 1 wt. % to about 10 wt. %, based on the total weight of the lifitegrast-containing ink binder. In some embodiment, the lifitegrast-containing ink binder of the present disclosure further includes a polymerization initiator in an amount of from about 0.05 wt. % to about 5 wt. %, or from about 0.1 wt. % to about 1 wt. %, based on the total weight of the lifitegrast-containing ink binder.
[0220] In some embodiments, the lifitegrast-containing ink binder of the present disclosure can further include one or more colorants. In some embodiments, a colorant can be a dye, or a pigment. In one embodiment, a colorant in the lifitegrast-containing ink binder of the present disclosure comprises at least one pigment. A colorant also may be a mixture of two or more pigments, which in combination provides a desired color, since any color can be obtained by merely mixing two or more primary colors together. The term “primary colors” refers to cyan, yellow, magenta, white, and black. A colorant may also be a mixture of at least one pigment and at least one dye. A person skill in the art will know how to select colorants.
[0221] In some embodiments, a pigment is a non-pearlescent pigment about 5 microns or smaller in size. Larger particles of a pigment can be ground into smaller particles. As one skilled in the art will appreciate, any number of methods known in the art can be used to grind pigment. For example, methods of reducing a pigment’s particle size include high speed mixers, Kady Mills (rotor stator dispersion device), colloid mills, homogenizers, microfluidizers, sonalators, ultrasonic mills, roll mills, ball mills, roller mills, vibrating ball mills, attritors, sand mills, varikinetic dispensers, three-roll mills, Banbury mixers, or other methods well known to those of skill in the art. In the case of pearlescent pigments, platelet breakage should be minimized during processing to maintain a sufficient level of dispersion. Pearlescent pigments require gentle handling duringmixing and they should not be ground, or subjected to prolonged mixing, milling or high shear since such operations can damage the pigments.
[0222] The lifitegrast-containing ink binder of the present disclosure can include the one or more colorants in an amount of from about 1 wt. % to about 40 wt. %, or from about 1 wt. % to about 30 wt. %, based on the total weight of the lifitegrast-containing ink binder.
[0223] The lifitegrast-containing ink binder of the present disclosure can be cured in an ophthalmic device mold such as a contact lens mold to form a lifitegrast-containing film on a molding surface of the mold. The lifitegrast-containing film comprises a polymer network with the one or more of the lifitegrast or salt thereof, the lifitegrast or salt thereof-containing monomer and the lifitegrast or salt thereof-containing polymer in the polymer network, and characterized by having a printed ink pattern. The lifitegrast-containing film can be obtained by applying, to at least a portion of a molding surface of an ophthalmic device mold, a lifitegrast-containing ink binder and curing the lifitegrast-containing ink binder utilizing one or more of heat (thermal cure) and / or radiation, such as ultraviolet light, visible light, or high energy radiation. The lifitegrast-containing film contains a first surface in contact with the molding surface and an exposed second surface, i.e., internal to an ophthalmic device-forming cavity of the ophthalmic device mold.
[0224] A lifitegrast-containing ink binder can be applied to a molding surface of a mold according to any printing technologies, such as, for example, pad transfer printing (or pad printing), or inkjet printing. It is understood that other types of printing technologies could also be used to print lenses and or molds. In some embodiments, the lifitegrast-containing ink binder can be applied to a molding surface of a mold such that the resulting pattern on the surface of the lens is in the form of concentric circles. In some embodiments, the lifitegrast-containing ink binder can be applied to a molding surface of a mold such that the resulting pattern on the surface of the lens is in the center of the lens. For example, in non-limiting illustrative embodiments, an ophthalmic device such as a colored contact lens disclosed herein can include a pupil section, an iris section having an area and circumferentially surrounding the pupil section, and a pattern extending across a portion of the area of the iris section in a geometrical configuration providing for delivering the lifitegrast or salt thereof to the eye of the wearer. In non-limiting illustrative embodiments, a contact lens disclosed herein can include a plurality of concentric rings of the lifitegrast-containing ink binder on the contact lens. In some embodiments, a contact lens can haveat least one surface of which includes a pupil section having a central circular area, an iris section having an area and circumferentially surrounding the pupil section and at least first and second concentric rings extending across a portion of the area of the iris section, wherein the first and second concentric rings are composed of the lifitegrast-containing ink binder.
[0225] Once the lifitegrast-containing ink binder has been applied to a molding surface of a mold, the lifitegrast-containing ink binder can be cured. Generally, polymerization can be carried out for about 1 minutes to about 45 minutes, and may or may not be under an inert atmosphere of, for example, nitrogen or argon.
[0226] A polymerization initiator may be included in the mixture to facilitate the polymerization step. Representative examples of free radical thermal polymerization initiators include organic peroxides such as acetyl peroxide, lauroyl peroxide, decanoyl peroxide, stearoyl peroxide, benzoyl peroxide, tertiarylbutyl peroxypivalate, peroxydicarbonate, and the like. Representative examples of diazo initiators include VAZO® 64, and VAZO® 67. Representative UV initiators are those known in the art and include benzoin methyl ether, benzoin ethyl ether, Darocure® 1173, 1164, 2273, 1116, 2959, 3331 (EM Industries) andlrgacure® 651 and 184 (Ciba-Geigy). Representative visible light initiators include IRGACURE 819 and other phosphine oxi detype initiators, and the like. Generally, the polymerization initiator will be employed in the lifitegrast-containing ink binder-forming mixture at a concentration of about 0.01 wt. % to about 5 wt. % of the total mixture.
[0227] Suitable molds for making the lifitegrast-containing film and ophthalmic devices having the lifitegrast-containing film on at least a portion of a surface thereof as discussed below are well known to a person skilled in the art. For example, a mold (for cast molding) generally comprises at least two mold sections (or portions) or mold halves, i.e. first and second mold halves. The first mold half defines a first molding (or optical) surface and the second mold half defines a second molding (or optical) surface. The first and second mold halves are configured to receive each other such that a lens forming cavity is formed between the first molding surface and the second molding surface. The molding surface of a mold half is the cavity-forming surface of the mold and in direct contact with lens-forming material. Virtually all materials known in the art for making molds can be used to make molds for making the lifitegrast-containing films and ophthalmic devices of the present disclosure. In some embodiments, polymeric materials include,for example, polyethylene, polypropylene, polystyrene or the like can be used. Other materials that allow UV light transmission could be used, such as quartz glass and sapphire.
[0228] Ophthalmic Device Having Lifitegrast-Containing Film
[0229] In accordance with a non-limiting illustrative embodiment, ophthalmic devices having the lifitegrast-containing film on at least a portion of a surface thereof can be made using the lifitegrast-containing film of the present disclosure. The lifitegrast-containing film has good adhesion to the ophthalmic devices by being covalently attached to the ophthalmic device material of the ophthalmic device through the polymerizable ethylenically unsaturated reactive group of the ink binder polymer, e.g., a polymerizable ethylenically unsaturated reactive group of the monomeric units derived from a hydroxyalkyl acrylate monomer where the acrylate moiety is attached to the backbone of the copolymer and the hydroxy moiety is end functionalized with a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate and a polymerizable ethylenically unsaturated reactive end group. It is believed that the ophthalmic device material upon curing forms an interpenetrating polymeric network with the cured or partially cured lifitegrast-containing film.
[0230] In some embodiments, ophthalmic devices having the lifitegrast-containing film of the present disclosure can be obtained by dispensing an ophthalmic device-forming mixture comprising an ophthalmic device-forming material into the contact lens mold having the lifitegrast-containing film as discussed above, curing the ophthalmic device-forming mixture comprising the ophthalmic device-forming material and releasing ophthalmic device from the mold. In some embodiments the ophthalmic device is a silicon contact lens which includes the step of hydrating the silicone contact lens to form the silicone contact lens having the lifitegrast-containing film on at least a portion of a surface thereof, whereby the lifitegrast-containing film detaches from the molding surface and becomes integral with the body of the silicone hydrogel contact lens without any ink domain expansion.
[0231] In some embodiments, the ophthalmic device-forming mixture can be cast directly in the molds containing the lifitegrast-containing film, e.g., polypropylene molds, from the ophthalmic device-forming mixtures, e.g., by spincasting and static casting methods. Spincasting methods are disclosed in U.S. Patent Nos. 3,408,429 and 3,660,545, and static casting methods are disclosed in U.S. Patent Nos. 4,113,224, 4,197,266, and 5,271,875. Spincasting methods involvecharging the ophthalmic device-forming mixtures to be polymerized to a mold, and spinning the mold in a controlled manner while exposing the mixture to a radiation source such as UV light. Static casting methods involve charging the ophthalmic device-forming mixture between two mold sections, one mold section shaped to form the anterior lens surface and the other mold section shaped to form the posterior lens surface, and curing the ophthalmic device-forming mixture while retained in the mold assembly to form an ophthalmic device, for example, by free radical polymerization of the ophthalmic device-forming mixture. Examples of free radical reaction techniques to cure the ophthalmic device material include thermal radiation, infrared radiation, electron beam radiation, gamma radiation, ultraviolet (UV) radiation, and the like; or combinations of such techniques may be used. U.S. Patent No. 5,271,875 describes a static cast molding method that permits molding of a finished ophthalmic device in a mold cavity defined by a posterior mold and an anterior mold. As an additional method, U.S. Patent No. 4,555,732 discloses a process where an excess of an ophthalmic device-forming mixture is cured by spincasting in a mold to form a shaped article having an anterior lens surface and a relatively large thickness, and the posterior surface of the cured spincast article is subsequently lathed to provide an ophthalmic device such as a contact lens having the desired thickness and posterior lens surface.
[0232] Polymerization may be facilitated by exposing the ophthalmic device-forming mixture to heat (thermal cure) and / or radiation, such as ultraviolet light, visible light, or high energy radiation. A polymerization initiator may be included in the ophthalmic device-forming mixture to facilitate the polymerization step. Representative examples of free radical thermal polymerization initiators include organic peroxides such as acetyl peroxide, lauroyl peroxide, decanoyl peroxide, stearoyl peroxide, benzoyl peroxide, tertiarylbutyl peroxypivalate, peroxydicarbonate, and the like. Representative examples of diazo initiators include VAZO 64, and VAZO 67. Representative UV initiators are those known in the art and include benzoin methyl ether, benzoin ethyl ether, Darocure® 1173, 1164, 2273, 1116, 2959, 3331 (EM Industries) and Irgacure® 651 and 184 (Ciba-Geigy). Representative visible light initiators include IRGACURE 819 and other phosphine oxide-type initiators, and the like. Generally, the initiator will be employed in the ophthalmic device-forming mixture at a concentration of about 0.01 to about 5 wt. % of the total mixture.
[0233] Polymerization is generally performed in a reaction medium, such as, for example, a solution or dispersion using a solvent, e.g., water or an alkanol containing from 1 to 4 carbon atoms such as methanol, ethanol or propan-2-ol. Alternatively, a mixture of any of the above solvents may be used.
[0234] Generally, polymerization can be carried out for about 15 minutes to about 72 hours, and under an inert atmosphere of, for example, nitrogen or argon. If desired, the resulting polymerization product can be dried under vacuum, e.g., for about 5 to about 72 hours, or left in an aqueous solution prior to use.
[0235] Polymerization of the ophthalmic device-forming mixtures will yield a polymer, that when hydrated, forms an ophthalmic device having a lifitegrast-containing film on at least a portion of a surface thereof with little to no ink domain expansion, i.e., the ink pattern of lifitegrast-containing film remains the same. In non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the ophthalmic devices such as silicone hydrogels disclosed herein can be high water content silicone hydrogels having an equilibrium water content of at least about 50 wt. %. In another illustrative embodiment, the silicone hydrogels disclosed herein can be high water content silicone hydrogels having an equilibrium water content of at least about 60 wt. %. In another illustrative embodiment, the silicone hydrogels disclosed herein can be high water content silicone hydrogels having an equilibrium water content of at least about 70 wt. %. In another illustrative embodiment, the silicone hydrogels disclosed herein can be high water content silicone hydrogels having an equilibrium water content of from about 50 wt. % to about 80 wt. %.
[0236] The ophthalmic devices obtained herein may be subjected to optional machining operations. For example, the optional machining steps may include buffing or polishing a lens edge and / or surface. Generally, such machining processes may be performed before or after the product is released from a mold part, e.g., a contact lens is dry released from the mold by employing vacuum tweezers to lift the lens from the mold, after which the lens is transferred by means of mechanical tweezers to a second set of vacuum tweezers and placed against a rotating surface to smooth the surface or edges. The lens may then be turned over in order to machine the other side of the lens.
[0237] In some embodiments, a contact lens may be transferred to individual lens packages containing a buffered saline solution. The saline solution may be added to the package either before or after transfer of the lens. Appropriate packaging designs and materials are known in the art. A plastic package is releasably sealed with a film. Suitable sealing films are known in the art and include foils, polymer films and mixtures thereof. The sealed packages containing the lenses are then sterilized to ensure a sterile product. Suitable sterilization means and conditions are known in the art and include, for example, autoclaving.
[0238] Suitable ophthalmic device-forming material includes, for example, a monofunctional silicone monomer represented by a structure of Formula VI:wherein R1, R2, R3and R4are independently hydrogen, an alkyl group, a halo alkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkenyl group, a haloalkenyl group, an aryl group and a heteroaryl group; R5, R6and R7are independently a straight or branched alkyl group; x is from 1 to 6; and y is from 3 to 15.
[0239] In some embodiments, R1, R2, R3and R4of the monofunctional silicone monomer represented by a structure of Formula VI are independently hydrogen, a Ci to C12 alkyl group, a Ci to C12 halo alkyl group, a C3 to C12 cycloalkyl group, a C3 to C12 heterocycloalkyl group, a C2 to C12 alkenyl group, a C2 to C12 haloalkenyl group, a Ce to C12 aromatic group and a Ce to C12 heteroaromatic group; R5, R6and R7are independently a straight or branched Ci to C12 alkyl group; x is from 1 to 6; and y is from 3 to 8.
[0240] In some embodiments, R1, R2, R3and R4of the monofunctional silicone monomer represented by a structure of Formula VI are independently hydrogen, a Ci to Ce alkyl group; R5, R6and R7are independently a straight or branched Ci to Ce alkyl group; x is from 1 to 6; and y is from 3 to 8.
[0241] In some embodiments, R1, R2, R3and R4are independently a Ci to C3 alkyl group; R5and R6are independently a Ci to C3 alkyl group; R7is a straight or branched C3 to Ce alkyl group; x is from 2 to 4; and y is from 3 to 15.
[0242] Representative examples of cycloalkylalkyl groups for use herein include, by way of example, a substituted or unsubstituted, cyclic ring-containing radical containing from about 4 to about 30 carbon atoms or from 3 to about 6 carbon atoms directly attached to the alkyl group which is then attached to the main structure of the monomer at any carbon from the alkyl group that results in the creation of a stable structure such as, for example, cyclopropylmethyl, cyclobutylethyl, cyclopentylethyl and the like, wherein the cyclic ring can optionally contain one or more heteroatoms, e.g., O and N, and the like to form a heterocycloalkylalkyl group.
[0243] Representative examples of cycloalkenyl groups for use herein include, by way of example, a substituted or unsubstituted cyclic ring-containing radical containing from about 3 to about 30 carbon atoms or from 3 to about 6 carbon atoms with at least one carbon-carbon double bond such as, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl and the like, wherein the cyclic ring can optionally contain one or more heteroatoms, e.g., O and N, and the like to form a heterocycloalkenyl group.
[0244] Representative examples of aryl groups for use herein include, by way of example, a substituted or unsubstituted, monoaromatic or polyaromatic radical containing from about 6 to about 30 carbon atoms or from about 6 to about 12 carbon atoms such as, for example, phenyl, naphthyl, tetrahydronapthyl, indenyl, biphenyl and the like, optionally containing one or more heteroatoms, e.g., O and N, and the like to form a heteroaryl group.
[0245] In an illustrative embodiment, the monofunctional silicone monomer represented by the structure of Formula VI is either commercially available from such sources as ShinEtsu or can be made by methods within the purview of one skilled in the art. For example, in an illustrative embodiment, the monofunctional silicone monomer represented by the structure of Formula VI can be prepared according to the following reaction Scheme VIII.Scheme VIIIo I N-(3-(chlorodimethylsilyl)propyl)acrylamide \ .O-Si"* ^Si 'O 6XSi**' S Li ex S Ii, O' S Ii, O' S Ii, O' S Ii Butyllithium _S|-0 \' \ I I I I I N-(3-(9-butyl-1 ,1 ,3,3,5,5,7,7,9,9-decamethylpentasiloxaneyl)propyl)acrylamide 2,2,4,4,6,6,8,8-octamethyl-1 ,3,5,7,2,4,6,8-tetraoxatetrasilocane
[0246] In some embodiments, the one or more monofunctional silicone monomers represented by a structure of Formula VI as disclosed herein can be present in the ophthalmic device-forming mixture in an amount ranging from about 5 wt. % to about 40 wt. %, based on the total weight of the ophthalmic device-forming mixture. In some embodiments, the one or more silicone monomers represented by a structure of Formula VI as disclosed herein can be present in the ophthalmic device-forming mixture in an amount ranging from about 7 wt. % to about 15 wt. %, based on the total weight of the ophthalmic device-forming mixture.
[0247] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more non-bulky organosilicon-containing monomers as discussed above.
[0248] Representative examples of the non-bulky organosilicon-containing monomers include:
[0249] M1EDS6: a compound having the structure and available from Gelest:
[0250] MCR-M11 : a compound having the structure:
[0251] M1-MCR-C12: a compound having the structure:wherein n is an average of 12.
[0252] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more polysiloxane prepolymers represented by a structure of Formula VII:R17R21R19wherein each V is an independently reactive functional end group and includes, by way of example, a hydroxyl-containing reactive functional end group, and an amine-containing reactive functional end group, R17to R22are independently straight or branched, substituted or unsubstituted C1-C30 alkyl group, a substituted or unsubstituted C3-C30 cycloalkyl group, a substituted or unsubstituted C4-C30 cycloalkylalkyl group, a substituted or unsubstituted C3-C30 cycloalkenyl group, a substituted or unsubstituted C6-C30 aryl group, and a substituted or unsubstituted C7-C30 arylalkyl group, and L is independently a linking group.
[0253] A hydroxyl-containing reactive functional end group for use herein is a group of the general formula -OH. Representative examples of amine-containing reactive functional end groups for use herein include, by way of example, a (meth)acrylamide-containing reactive functional end group.
[0254] Linking group L is independently a straight or branched alkyl group, cycloalkyl group, an aryl group, an ether or poly ether group, and an ester group as defined herein.
[0255] A representative example of a polysiloxane prepolymer is as follows:O O37
[0256] Methods for making the polysiloxane prepolymers described herein are well known and within the purview of one skilled in the art. In addition, the polysiloxane prepolymers are also commercially available from such sources as, for example, Gelest, Silar, Shin-Etsu, Momentive and Siltech.
[0257] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more bulky silicone-containing monomers as discussed above.
[0258] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more silicone-containing vinyl carbonate or vinyl carbamate monomers. Suitable one or more silicone-containing vinyl carbonate or vinyl carbamate monomers include, for example, l,3-bis[4-vinyloxycarbonyloxy)but-l-yl]tetramethyl-disiloxane; 3-(trimethylsilyl)propyl vinyl carbonate; 3-(vinyloxycarbonylthio)propyl-[tris(trimethylsiloxy)silane]; 3-[tris(trimethylsiloxy)silyl]propyl vinyl carbamate; 3-[tris(trimethylsiloxy)silyl]propyl allyl carbamate; 3-[tris(trimethylsiloxy)silyl]propyl vinyl carbonate; t-butyldimethylsiloxyethyl vinyl carbonate; trimethylsilylethyl vinyl carbonate; trimethylsilylmethyl vinyl carbonate and the like and mixtures thereof.
[0259] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more polyurethanepolysiloxane macromonomers (also sometimes referred to as prepolymers), which may have hard-soft-hard blocks like traditional urethane elastomers. They may be end-capped with a hydrophilic monomer such as HEMA. Examples of such silicone urethanes are disclosed in a variety or publications, including Lai, Yu-Chin, “The Role of Bulky Polysiloxanylalkyl Methacrylates in Polyurethane-Polysiloxane Hydrogels,” Journal of Applied Polymer Science, Vol. 60, 1193-1199 (1996). PCT Published Application No. WO 96 / 31792 discloses examples of such monomers, which disclosure is hereby incorporated by reference in its entirety. Further examples of silicone urethane monomers are represented by Formulae VIII and IX:E(*D*A*D*G)a*D*A*D*E’; or (VIII)E(*D*G*D*A)a*D*A*D*E’; or (IX) wherein:D independently denotes an alkyl diradical, an alkyl cycloalkyl diradical, a cycloalkyl diradical, an aryl diradical or an alkylaryl diradical having 6 to about 30 carbon atoms;G independently denotes an alkyl diradical, a cycloalkyl diradical, an alkyl cycloalkyl diradical, an aryl diradical or an alkylaryl diradical having 1 to about 40 carbon atoms and which may contain ether, thio or amine linkages in the main chain;* denotes a urethane or ureido linkage;a is at least 1 ;A independently denotes a divalent polymeric radical of Formula X:- (CH2)m, - Si— O— Si— (CH2)m. -wherein each Rsindependently denotes an alkyl or fluoro-substituted alkyl group having 1 to about 10 carbon atoms which may contain ether linkages between the carbon atoms; m' is at least 1; and p is a number that provides a moiety weight of about 400 to about 10,000;each of E and E' independently denotes a polymerizable unsaturated organic radical represented by Formula XI:(CH2)W- (X)x- (Z)z- (Ar)y- R5R4(XI) wherein: R3is hydrogen or methyl;R4is hydrogen, an alkyl radical having 1 to 6 carbon atoms, or a — CO — Y — R6radical wherein Y is — O— , — S— or — NH— ;R5is a divalent alkylene radical having 1 to about 10 carbon atoms;R6is a alkyl radical having 1 to about 12 carbon atoms;X denotes — CO — or — OCO — ;Z denotes — O — or — NH — ;Ar denotes an aromatic radical having about 6 to about 30 carbon atoms;w is 0 to 6; x is 0 or 1 ; y is 0 or 1 ; and z is 0 or 1.
[0260] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more silicone-containing urethane monomers represented by Formula XII:H H H HE" — OCN1R7N ICOCH2CH2OCH2CH2OCN I R7N IC o o o o(XII) wherein m is at least 1 and is preferably 3 or 4, a is at least 1 and preferably is 1 , p is a number which provides a moiety weight of about 400 to about 10,000 and is preferably at least about 30, R7is a diradical of a diisocyanate after removal of the isocyanate group, such as the diradical of isophorone diisocyanate, and each E" is a group represented by:
[0261] In another embodiment, a silicone hydrogel material comprises (in bulk, that is, in the ophthalmic device-forming mixture that is copolymerized) about 5 to about 50 percent, or from about 10 to about 25, by weight of one or more silicone macromonomers, about 5 to about 75 percent, or about 30 to about 60 percent, by weight of one or more polysiloxanylalkyl (meth)acrylic monomers, and about 10 to about 50 percent, or about 20 to about 40 percent, by weight of a hydrophilic monomer. In general, the silicone macromonomer is a poly(organosiloxane) capped with an unsaturated group at two or more ends of the molecule. In addition to the end groups in the above structural Formulas, U.S. Patent No. 4,153,641 discloses additional unsaturated groups, including acryloxy or methacryloxy. Fumarate-containing materials such as those disclosed in U.S. Patent Nos. 5,310,779; 5,449,729 and 5,512,205 are also useful substrates in accordance with the non-limiting embodiments described herein. The silane macromonomer may be a silicone-containing vinyl carbonate or vinyl carbamate or a polyurethane-polysiloxane having one or more hard-soft-hard blocks and end-capped with a hydrophilic monomer.
[0262] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more monomers of Formula XIII:n(xiii) wherein X is the residue of a ring opening agent; L is the same or different and is a linking group or a bond; V is an ethylenically unsaturated polymerizable group; Ri, R2, R3, R4, Rs, Re are independently hydrogen, an alkyl group, a haloalkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkenyl group, a halo alkenyl group, or an aromatic group; R7 and Rs are independently hydrogen or an alkyl group wherein at least one of R7 or Rs is hydrogen; y is 2-7 and n is 1-100.
[0263] Ring opening agents are well known in the literature. Non-limiting examples of anionic ring opening agents include alkyl lithium, an alkoxide, trialkylsiloxylithium wherein the alkyl group may or may not contain halo atoms.
[0264] Linking groups can be any divalent radical or moiety and include substituted or unsubstituted alkyl, alkyl ether, alkenyls, alkenyl ethers, halo alkyls, substituted or unsubstituted siloxanes, and monomers capable of propagating ring opening.
[0265] Ethylenically unsaturated polymerizable groups are well known to those skilled in the art and can be any of those discussed above.
[0266] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more monomers of Formula XIV:wherein L is the same or different and is a linking group or a bond; V is the same or different and is an ethylenically unsaturated polymerizable group; Ri, R2, R3, R4, Rs, Re and R9 are independently hydrogen, an alkyl group, a haloalkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkenyl group, a halo alkenyl group, or an aromatic group; R7 and Rs are independently hydrogen or an alkyl group wherein at least one of R7 or Rs is hydrogen; y is 2-7 and n is 1-100.
[0267] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more monomers of Formulae XV and XVI:(XV) wherein R9, Rio and Rn are independently hydrogen, an alkyl group, a haloalkyl group or other substituted alkyl groups; n is as defined above and n1is 0-10; and,wherein n is 1 to 100, or n is 2 to 80, or n is 3 to 20, or n is 5 to 15.
[0268] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more monomers of Formulas XVII-XXI:(M1- EDS6- TMS)(XVI),(XVIII)1215(XXI).
[0269] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more monomers of Formulas XXII-XXIV:(XXII),(XXIII), and(XXIV)
[0270] wherein R9, Rio and Rn are independently hydrogen, an alkyl group, a haloalkyl group or other substituted alkyl groups and n and n1are as defined above.
[0271] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more monomers of Formulas XXV-XXVII:(XXV),(XXVII)
[0272] wherein n is as defined above and X' is a counterion to provide an overall neutral charge.
[0273] Counterions capable of providing an overall neutral charge are well known to those of ordinary skill in the art and would include, for example, halide ions.
[0274] Suitable ophthalmic device-forming material further includes, for example, as a class of representative ophthalmic device-forming material, one or more monomers of Formula XXVIII:1 n1 1.si^^Lo. S‘ | O | 0I1T J 7(XXVIII).
[0275] In accordance with one or more additional non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the one or more ophthalmic device-forming material can be present in the ophthalmic device-forming mixture in a majoramount. In accordance with one or more additional non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the one or more ophthalmic deviceforming material can be present in the ophthalmic device-forming mixture in an amount greater than about 50 wt. %, based on the total weight of the ophthalmic device-forming mixture. In some embodiments, the one or more ophthalmic device-forming material can be present in the ophthalmic device-forming mixture in an amount greater than about 50 wt. % and up to 95 wt. %, based on the total weight of the ophthalmic device-forming mixture.
[0276] The above silicone materials are merely exemplary, and other materials for use as substrates that have been disclosed in various publications and are being continuously developed for use in contact lenses and other silicone hydrogels can also be used. For example, a silicone hydrogel can be formed from at least a cationic monomer such as cationic silicone-containing monomers or cationic fluorinated silicone-containing monomers.
[0277] In non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the ophthalmic device-forming mixture can further contain one or more hydrophilic comonomers. Suitable hydrophilic comonomers include, for example, unsaturated carboxylic acids, acrylamides, vinyl lactams, hydroxyl-containing-(meth)acrylates, hydrophilic vinyl carbonates, hydrophilic vinyl carbamates, hydrophilic oxazolones, and poly(alkene glycols) functionalized with polymerizable groups and the like and mixtures thereof. Representative examples of unsaturated carboxylic acids include, but are not limited to, methacrylic acid, acrylic acid and the like and mixtures thereof. Representative examples of acrylamides include, but are not limited to, alkylamides such as N,N-dimethylacrylamide, N,N-dimethylmethacrylamide and the like and mixtures thereof. Representative examples of cyclic lactams include, but are not limited to, N-vinyl-2 -pyrrolidone, N-vinyl caprolactam, N-vinyl-2-piperidone and the like and mixtures thereof. Representative examples of hydroxyl-containing (meth)acrylates include, but are not limited to, 2-hydroxyethyl methacrylate (HEMA), glycerol methacrylate and the like and mixtures thereof.
[0278] Additional hydrophilic comonomers include, for example, the hydrophilic vinyl carbonate or vinyl carbamate monomers disclosed in U.S. Patent No. 5,070,215, and the hydrophilic oxazolone monomers disclosed in U.S. Patent No. 4,910,277. Other suitable silicone hydrogel-forming hydrophilic comonomers will be apparent to one skilled in the art. Mixtures ofthe foregoing hydrophilic comonomers can also be used in the ophthalmic device-forming mixtures herein.
[0279] In accordance with one or more additional non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the one or more hydrophilic comonomers can be present in the ophthalmic device-forming mixture in an amount ranging from about 20 wt. % to about 60 wt. %, based on the total weight of the ophthalmic device-forming mixture. In another illustrative embodiment, the one or more hydrophilic comonomers can be present in the ophthalmic device-forming mixture in an amount ranging from about 25 wt. % to about 45 wt. %, based on the total weight of the ophthalmic device-forming mixture.
[0280] In non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the ophthalmic device-forming mixture can further contain one or more crosslinking agents. Suitable crosslinking agents for use herein are known in the art. For example, in non-limiting illustrative embodiments, suitable one or more cross-linking agents include one or more crosslinking agents containing at least two ethylenically unsaturated reactive end groups. In one embodiment, the ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups. In another embodiment, the ethylenically unsaturated reactive end groups are non-(meth)acrylate reactive end groups. In one embodiment, the ethylenically unsaturated reactive end groups are a combination of one or more (meth)acrylate-containing reactive end groups and one or more non-(meth)acrylate reactive end groups.
[0281] In an illustrative embodiment, useful one or more crosslinking agents containing at least two ethylenically unsaturated reactive end groups include, for example, one or more di-, trior tetra(meth)acrylate-containing crosslinking agents. In an illustrative embodiment, useful one or more di-, tri- or tetra(meth)acrylate-containing crosslinking agents include, for example, alkanepolyol di-, tri- or tetra(meth)acrylate-containing crosslinking agents such as, for example, one or more alkylene glycol di(meth)acrylate crosslinking agents, one or more alkylene glycol tri(meth)acrylate crosslinking agents, one or more alkylene glycol tetra(meth)acrylate crosslinking agents, one or more alkanediol di(meth)acrylate crosslinking agents, alkanediol tri(meth)acrylate crosslinking agents, alkanediol tetra(meth)acrylate crosslinking agents, agents, one or more alkanetriol di(meth)acrylate crosslinking agents, alkanetriol tri(meth)acrylate crosslinking agents, alkanetriol tetra(meth)acrylate crosslinking agents, one or more alkanetetraol di(meth)acrylatecrosslinking agents, alkanetetraol tri(meth)acrylate crosslinking agents, alkanetetraol tetra(meth)acrylate crosslinking agents and the like and mixtures thereof.
[0282] In an illustrative embodiment, one or more alkylene glycol di(meth)acrylate crosslinking agents include tetraethylene glycol dimethacrylate, ethylene glycol di(meth)acrylates having up to about 10 ethylene glycol repeating units, butyleneglycol di(meth)acrylate and the like. In one embodiment, one or more alkanediol di(meth)acrylate crosslinking agents include butanediol di(meth)acrylate crosslinking agents, hexanediol di(meth)acrylate and the like. In one embodiment, one or more alkanetriol tri(meth)acrylate crosslinking agents are trimethylol propane trimethacrylate crosslinking agents. In one embodiment, one or more alkanetetraol tetra(meth)acrylate crosslinking agents are pentaerythritol tetramethacrylate crosslinking agents.
[0283] In a non-limiting illustrative embodiment, suitable crosslinking agents include, for example, ethylene glycol diacrylate, diethylene glycol diacrylate, allyl acrylate, 1,3-propanediol diacrylate, 2,3-propanediol diacrylate, 1,6-hexanediol diacrylate, 1 ,4-butanediol diacrylate, triethylene glycol diacrylate, cyclohexane-l,l-diyldimethanol diacrylate, 1 ,4-cyclohexanediol diacrylate, 1,3 -adamantanediol diacrylate, 1,3 -adamantanedimethyl diacrylate, 2,2-diethyl-l,3-propanediol diacrylate, 2,2-diisobutyl-l,3-propanediol diacrylate, 1,3-cyclohexanedimethyl diacrylate, 1 ,4-cyclohexanedimethyl diacrylate; neopentyl glycol diacrylate, tetraethyleneglycol diacrylate, polyethyleneglycol diacrylate; and their corresponding methacrylates.
[0284] In a non-limiting illustrative embodiment, suitable crosslinking agents include, for example, 1 ,4-butanediol diacrylate, 1,4-butanediol dimethacrylate, ethylene glycol dimethacrylate, diethylene glycol diacrylate, diethylene glycol dimethacrylate, triethylene glycol diacrylate, triethylene glycol dimethacrylate, tetraethylene glycol diacrylate, tetraethylene glycol dimethacrylate, 1,3-propanediol diacrylate, 1,3-propanediol dimethacrylate, 1,6-hexanediol diacrylate, 1,6-hexanediol dimethacrylate, poly(ethylene glycol) diacrylate (Mn = 700 Daltons), poly(ethylene glycol) dimethacrylate (Mn = 700 Daltons), and poly(ethylene glycol) dimethacrylate (Mn = 1000 Daltons).
[0285] In one embodiment, the one or more crosslinking agents containing at least two ethylenically unsaturated reactive end groups include at least one allyl-containing reactive end group and at least one (meth)acrylate-containing reactive end group. In an illustrative embodiment, the one or more crosslinking agents can be allyl methacrylate.
[0286] In non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the one or more crosslinking agents can be present in the ophthalmic device-forming mixture in an ophthalmic device-forming amount. In non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the one or more crosslinking agents are present in the ophthalmic device-forming mixture in an amount of about 0.1 wt. % to about 3.0 wt. %, based on the total weight of the ophthalmic device-forming mixture. In non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the one or more crosslinking agents are present in the ophthalmic device-forming mixture in an amount of about 0.2 wt. % to about 1.0 wt. %, based on the total weight of the ophthalmic device-forming mixture.
[0287] In accordance with one or more additional non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the ophthalmic device-forming mixture can further contain one or more additional comonomers. In an illustrative embodiment, the one or more additional comonomers can include, for example, both an ethylenically unsaturated group (that permits the monomer to copolymerize with the hydrophilic comonomer) and an epoxide group (that does not react with the hydrophilic comonomer but remains to react with the copolymer). Suitable additional comonomers include, for example, glycidyl methacrylate, glycidyl acrylate, glycidyl vinylcarbonate, glycidyl vinylcarbamate, 4-vinyl-l-cyclohexene-l,2-epoxide and the like.
[0288] In non-limiting illustrative embodiments, the one or more additional comonomers can be present in the ophthalmic device-forming mixture in an amount ranging from about 1 wt. % to about 20 wt. %, based on the total weight of the ophthalmic device-forming mixture. In another illustrative embodiment, the one or more additional comonomers can be present in the ophthalmic device-forming mixture in an amount ranging from about 3 wt. % to about 10 wt. %, based on the total weight of the ophthalmic device-forming mixture.
[0289] In non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the ophthalmic device-forming mixture can further contain a reactive (polymerizable) ultraviolet (UV) light absorber and / or a reactive blue-light absorber. Suitable reactive UV light absorbers can be any known reactive UV light absorber. In non-limiting illustrative embodiments, suitable reactive UV light absorbers include, for example, 2-(2’-hydroxy-3’-methallyl-5’-methylphenyl)benzotriazole, commercially available as o-Methallyl TinuvinP (“oMTP”) from Polysciences, Inc., Warrington, Pa., 3-(2H-benzo[d][l,2,3]triazol-2-yl)-4-hydroxyphenylethyl methacrylate, and 2-(3-(tert-butyl)-4-hydroxy-5-(5 -methoxy -2H-benzo[d][l,2,3]triazol-2-yl)phenoxy)ethyl methacrylate.
[0290] In one illustrative embodiment, suitable UV light absorbers include, for example, one or more compounds of the following formulas:(2-Propenoic acid, 2-methyl,2-(4-benzoyl-3-hydroxyphenoxy)-l-[(4-benzoyl3-hydroxyphenoxy)methyl ester),HOThese compounds are merely illustrative and not intended to be limiting. Any known UV blocker or later developed UV blocker is contemplated for use herein.
[0291] In illustrative embodiments, the UV light absorbers can be present in the ophthalmic device-forming mixture in an amount ranging from about 0.1 wt. % to about 5 wt. %, based on the total weight of the ophthalmic device-forming mixture. In another illustrative embodiment, the UV light absorbers can be present in the ophthalmic device-forming mixture in an amount ranging from about 1.5 wt. % to about 2.5 wt. %, based on the total weight of the ophthalmic device-forming mixture. In yet another non-limiting illustrative embodiment, the UV light absorbers can be present in the ophthalmic device-forming mixture in an amount rangingfrom about 1.5 wt. % to about 2 wt. %, based on the total weight of the ophthalmic device-forming mixture.
[0292] Many reactive blue-light absorbing compounds are known. Preferred reactive bluelight absorbing compounds are those described in U.S. Pat. Nos. 5,470,932; 8,207,244; and 8,329,775, the contents of which are hereby incorporated by reference. In one embodiment, a blue-light absorbing dye is N-2-[3-(2’-methylphenylazo)-4-hydroxyphenyl]ethyl methacrylamide. In illustrative embodiments, the blue-light absorbers can be present in the ophthalmic deviceforming mixture in an amount ranging from about 0.005 wt. % to about 1 wt. %, based on the total weight of the ophthalmic device-forming mixture. In another illustrative embodiment, the bluelight absorbers can be present in the ophthalmic device-forming mixture in an amount ranging from about 0.01 wt. % to about 1 wt. %, based on the total weight of the ophthalmic device-forming mixture.
[0293] In non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the ophthalmic device-forming mixture can further contain a diluent. Suitable diluents include, for example, at least one or more boric acid esters of a Ci to Cs monohydric alcohol, water-soluble or partly water-soluble monohydric alcohols and mixtures thereof. In one embodiment, a diluent includes, for example, at least one or more boric acid esters of a Ci to Cs monohydric alcohol. Suitable boric acid esters of a Ci to Cs monohydric alcohol include, for example, trimethyl borate, triethyl borate, tri-n-propyl borate, triisopropyl borate, tri-n-butyl borate, and tri-tert-butyl borate. Suitable water-soluble or partly water-soluble monohydric alcohols include, for example, monohydric alcohols having from 1 to 5 carbon atoms such as methanol, ethanol, isopropyl alcohol, 1 -propanol, t-butyl alcohol, 2-butyl alcohol, 2-methyl-l-propanol, t-amyl alcohol and other C5 isomers.
[0294] In non-limiting illustrative embodiments, as may be combined with one or more of the preceding paragraphs, the ophthalmic device-forming mixture contains about 5 wt. % to about 50 wt. % of the diluent, based on the total weight of the ophthalmic device-forming mixture. In one embodiment, the ophthalmic device-forming mixture contains about 15 wt. % to about 30 wt. % of the diluent, based on the total weight of the ophthalmic device-forming mixture.
[0295] The ophthalmic device-forming mixture may further contain, as necessary and within limits not to impair the purpose and effect of the illustrative embodiments, various additivessuch as an antioxidant, coloring agent, lubricant, internal wetting agent, toughening agent and the like and other constituents as are well known in the art.
[0296] As one skilled in the art will readily appreciate other steps may be included in the molding and packaging process described above. Such other steps can include, for example, coating the formed lens, surface treating the lens during formation (e.g., via mold transfer), inspecting the lens, discarding defective lenses, cleaning the mold halves, reusing the mold halves, and the like and combinations thereof.
[0297] According to an aspect of the present disclosure, a lifitegrast-containing ink binder comprises:
[0298] (a) a solvent,
[0299] (b) an ink binder polymer comprising a polymerizable ethylenically unsaturated reactive group, and
[0300] (c) one or more of a lifitegrast or a salt thereof, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group and a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group.
[0301] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the ink binder polymer comprising the polymerizable ethylenically unsaturated reactive group comprises a reaction product of (i) a copolymer comprising (1) monomeric units derived from a hydroxyalkyl acrylate monomer, and (2) monomeric units derived from a hydrophilic monomer having an ethylenically unsaturated reactive group, with (ii) a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive end group.
[0302] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the copolymer comprises (1) monomeric units derived from a hydroxy ethyl acrylate monomer, and (2) monomeric units derived from N-vinylpirrolidone.
[0303] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive end group is selected from the group consisting of 2-isocyanatoethyl acrylate, 3-isocyanatopropyl acrylate, 2-isocyanatoethyl methacrylate, 1 -methyl-2-isocyanatoethyl methacrylate, 1, 1-dimethy 1 -2-isocyanatoethyl acrylate, (meth)acryloyl chloride and vinyl chloroformate.
[0304] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the copolymer comprises from about 5 mol % to about 95 mol % of the monomeric units derived from the hydroxyalkyl acrylate monomer and from about 5 mol % to about 95 mol % of the monomeric units derived from the hydrophilic monomer.
[0305] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the ink binder polymer comprising the polymerizable ethylenically unsaturated reactive group comprises a silicone prepolymer comprising a reaction product of (i) a copolymerization product of a polymerization composition comprising (1) an alkylacrylamide monomer, (2) a hydroxyalkyl acrylate monomer, (3) a non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive group, and (4) a bulky siloxane monomer having an ethylenically unsaturated reactive group, with (ii) a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive group; and (c) one or more a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group and a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and an ethylenically unsaturated reactive group.
[0306] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the alkylacrylamide monomer is N,N-dimethylacrylamide.
[0307] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the hydroxyalkyl acrylate monomer is a hydroxyethyl acrylate monomer.
[0308] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the non-bulky organosilicon-containing monomer is represented by the following structure:
[0309] wherein V is ethylenically unsaturated polymerizable group, L is a linker group or a bond; R1, R2, R3, R4, R5, R6, R7, R8, and R9are independently hydrogen an alkyl group, a haloalkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkenyl group, a halo alkenyl group, or an aromatic group; R10and R11are independently hydrogen or alkyl wherein at least one of R10and R11is hydrogen; y is 2 to 7 and n is 1 to 100, or the non-bulky organosilicon-containing monomer is represented by the following structure:° f4rR1\JL RA4i-(0Si)-Ri5T IvI / aR14R14
[0310] wherein R12is H or methyl; X is O or NR16; wherein R16is hydrogen or Ci to C4 alkyl, which may be further substituted with one or more hydroxyl groups; R13is a divalent alkyl group, which may further be functionalized with a group selected from the group consisting of an ether group, a hydroxyl group, a carbamate group and combinations thereof; each R14is independently a phenyl or Ci to C4 alkyl which may be substituted with fluorine, hydroxyl or an ether; R15is a Ci to C4 alkyl; and a is 2 to 50.
[0311] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the bulky siloxane monomer is represented by the following structure:R18— Si— R-R18
[0312] wherein X denotes -O- or -NR19- where each R19is hydrogen or a C1-C4 alkyl; R17independently denotes hydrogen or methyl; each R18independently denotes a Ci-Ce alkyl radical, a phenyl radical or a group represented by the following structure:R18'— Si— R18'R18'
[0313] wherein each R18' independently denotes a Ci-Ce alkyl radical or a phenyl radical; and h is 1 to 10; or the following structure:R18R1— Si — R18
[0314] wherein X denotes -NR19-; wherein R19denotes hydrogen or a C1-C4 alkyl; R17denotes hydrogen or methyl; each R18independently denotes a Ci-Ce alkyl radical, a phenyl radical or a group represented by the following structure:R18'— Si— R18'R18'
[0315] wherein each R18independently denotes a Ci-Ce alkyl radical or a phenyl radical; and h is 1 to 10.
[0316] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive end group is selected from the group consisting of 2-isocyanatoethyl acrylate, 3-isocyanatopropyl acrylate, 2-isocyanatoethyl methacrylate, 1 -methyl-2-isocyanatoethyl methacrylate, 1, 1-dimethy 1 -2-isocyanatoethyl acrylate, (meth)acryloyl chloride and vinyl chloroformate.
[0317] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the silicone prepolymer comprises:
[0318] from about 50 to about 400 repeating units of monomeric units derived from the alkylacrylamide monomer,
[0319] from about 50 to about 200 repeating units of monomeric units derived from the hydroxyalkyl acrylate monomer,
[0320] from about 5 to about 20 repeating units of monomeric units derived from the hydroxyalkyl acrylate monomer where the acrylate moiety is attached to the backbone of the copolymer and the hydroxy moiety is end functionalized with a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate and a polymerizable ethylenically unsaturated reactive end group,
[0321] from about 20 to about 300 repeating units of monomeric units derived from the non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive end group, and
[0322] from about 1 to about 400 repeating units of monomeric units derived from the bulky siloxane monomer having an ethylenically unsaturated reactive end group.
[0323] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the releasable linking group is attached to the lifitegrast or salt thereof and the ethylenically unsaturated reactive group via a pH-labile bond, an acid-labile bond, a base-labile bond, an oxidatively labile bond, a metabolically labile bond, a biochemically labile bond, an enzyme-labile bond, a chemical-labile bond or a photo-labile bond.
[0324] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the releasable linking group is one of an ester group or a nitrobenzene group and the ethylenically unsaturated reactive group is a methacrylate group.
[0325] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the one or more of the one or more of a lifitegrast or a salt thereof, the lifitegrast or salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group or the lifitegrast or salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group is the lifitegrast or salt thereof.
[0326] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the one or more of the one or more of a lifitegrast or a salt thereof, the lifitegrast or salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group or the lifitegrast or salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group is the lifitegrast or salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group.
[0327] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof-containing polymer comprises a lifitegrast or a salt thereof-containing glycosaminoglycan polymer.
[0328] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof-containing glycosaminoglycan polymer comprises lifitegrast or a salt thereof attached to a glycosaminoglycan polymer via a releasable linking group.
[0329] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the releasable linking group attached to the lifitegrast or salt thereof and theglycosaminoglycan polymer is one of a pH-labile bond, an acid-labile bond, a base-labile bond, an oxidatively labile bond, a metabolically labile bond, a biochemically labile bond, an enzyme-labile bond, a chemical-labile bond or a photo-labile bond.
[0330] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof-containing glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and a side chain comprising a reactive functionality complementary to a reactive functionality of lifitegrast or a salt thereof to provide a lifitegrast or a salt thereof residue grafted onto the polymer backbone.
[0331] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof residue is grafted onto the polymer backbone via an ester bond.
[0332] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof residue is grafted onto the polymer backbone via a nitrobenzene group.
[0333] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof-containing polymer further comprises the ethylenically unsaturated reactive group.
[0334] According to another aspect of the present disclosure, an ophthalmic device comprising a lifitegrast-containing film on at least a portion of a surface thereof, the lifitegrast-containing film comprising a polymerization product of a lifitegrast-containing ink binder comprising (a) a solvent, (b) an ink binder polymer comprising a polymerizable ethylenically unsaturated reactive group, and (c) one or more of a lifitegrast or a salt thereof, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group and a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group.
[0335] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the ink binder polymer comprising the polymerizable ethylenically unsaturated reactive group comprises a reaction product of (i) a copolymer comprising (1) monomeric units derived from a hydroxyalkyl acrylate monomer, and (2) monomeric units derived from a hydrophilic monomer having an ethylenically unsaturated reactive group, with (ii) amonomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive end group.
[0336] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the copolymer comprises (1) monomeric units derived from a hydroxy ethyl acrylate monomer, and (2) monomeric units derived from N-vinylpirrolidone.
[0337] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive end group is selected from the group consisting of 2-isocyanatoethyl acrylate, 3-isocyanatopropyl acrylate, 2-isocyanatoethyl methacrylate, 1 -methyl-2-isocyanatoethyl methacrylate, 1, 1-dimethy 1 -2-isocyanatoethyl acrylate, (meth)acryloyl chloride and vinyl chloroformate.
[0338] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the copolymer comprises from about 5 mol % to about 95 mol % of the monomeric units derived from the hydroxyalkyl acrylate monomer and from about 5 mol % to about 95 mol % of the monomeric units derived from the hydrophilic monomer.
[0339] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the ink binder polymer comprising the polymerizable ethylenically unsaturated reactive group comprises a silicone prepolymer comprising a reaction product of (i) a copolymerization product of a polymerization composition comprising (1) an alkylacrylamide monomer, (2) a hydroxyalkyl acrylate monomer, (3) a non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive group, and (4) a bulky siloxane monomer having an ethylenically unsaturated reactive group, with (ii) a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive group.
[0340] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the alkylacrylamide monomer is N,N-dimethylacrylamide.
[0341] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the hydroxyalkyl acrylate monomer is a hydroxyethyl acrylate monomer.
[0342] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the non-bulky organosilicon-containing monomer is represented by the following structure:
[0343] wherein V is ethylenically unsaturated polymerizable group, L is a linker group or a bond; R1, R2, R3, R4, R5, R6, R7, R8, and R9are independently hydrogen an alkyl group, a haloalkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkenyl group, a halo alkenyl group, or an aromatic group; R10and R11are independently hydrogen or alkyl wherein at least one of R10and R11is hydrogen; y is 2 to 7 and n is 1 to 100, or the non-bulky organosilicon-containing monomer is represented by the following structure:° r rR1\JL R141-(OS1)-R15T |v| / aR14R14
[0344] wherein R12is H or methyl; X is O or NR16; wherein R16is hydrogen or Ci to C4 alkyl, which may be further substituted with one or more hydroxyl groups; R13is a divalent alkyl group, which may further be functionalized with a group selected from the group consisting of an ether group, a hydroxyl group, a carbamate group and combinations thereof; each R14is independently a phenyl or Ci to C4 alkyl which may be substituted with fluorine, hydroxyl or an ether; R15is a Ci to C4 alkyl; and a is 2 to 50.
[0345] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the bulky siloxane monomer is represented by the following structure:R18— Si— R-R18
[0346] wherein X denotes -O- or -NR19- where each R19is hydrogen or a C1-C4 alkyl; R17independently denotes hydrogen or methyl; each R18independently denotes a Ci-Ce alkyl radical, a phenyl radical or a group represented by the following structure:R18'— Si— R18'R18'
[0347] wherein each R18' independently denotes a Ci-Ce alkyl radical or a phenyl radical; and h is 1 to 10; or the following structure:R18R1— Si — R18
[0348] wherein X denotes -NR19-; wherein R19denotes hydrogen or a C1-C4 alkyl; R17denotes hydrogen or methyl; each R18independently denotes a Ci-Ce alkyl radical, a phenyl radical or a group represented by the following structure:R18'— Si— R18'R18'
[0349] wherein each R18independently denotes a Ci-Ce alkyl radical or a phenyl radical; and h is 1 to 10.
[0350] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive end group is selected from the group consisting of 2-isocyanatoethyl acrylate, 3-isocyanatopropyl acrylate, 2-isocyanatoethyl methacrylate, 1 -methyl-2-isocyanatoethyl methacrylate, 1, 1-dimethy 1 -2-isocyanatoethyl acrylate, (meth)acryloyl chloride and vinyl chloroformate.
[0351] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the silicone prepolymer comprises:
[0352] from about 50 to about 400 repeating units of monomeric units derived from the alkylacrylamide monomer,
[0353] from about 50 to about 200 repeating units of monomeric units derived from the hydroxyalkyl acrylate monomer,
[0354] from about 5 to about 20 repeating units of monomeric units derived from the hydroxyalkyl acrylate monomer where the acrylate moiety is attached to the backbone of the copolymer and the hydroxy moiety is end functionalized with a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate and a polymerizable ethylenically unsaturated reactive end group,
[0355] from about 20 to about 300 repeating units of monomeric units derived from the non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive end group, and
[0356] from about 1 to about 400 repeating units of monomeric units derived from the bulky siloxane monomer having an ethylenically unsaturated reactive end group.
[0357] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the releasable linking group is attached to the lifitegrast or salt thereof and the ethylenically unsaturated reactive group via a pH-labile bond, an acid-labile bond, a base-labile bond, an oxidatively labile bond, a metabolically labile bond, a biochemically labile bond, an enzyme-labile bond, a chemical-labile bond or a photo-labile bond.
[0358] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the releasable linking group is one of an ester group or a nitrobenzene group.
[0359] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the releasable linking group is one of an ester group or a nitrobenzene group and the ethylenically unsaturated reactive group is a methacrylate group.
[0360] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the one or more of the one or more of a lifitegrast or a salt thereof, the lifitegrast or salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group or the lifitegrast or salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group is the lifitegrast or salt thereof.
[0361] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the one or more of the one or more of a lifitegrast or a salt thereof, the lifitegrast or salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group or the lifitegrast or salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group is the lifitegrast or salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group.
[0362] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof-containing polymer comprises a lifitegrast or a salt thereof-containing glycosaminoglycan polymer.
[0363] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof-containing hydrophilic polymer comprises lifitegrast or a salt thereof attached to a glycosaminoglycan polymer via a releasable linking group.
[0364] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the releasable linking group attached to the lifitegrast or salt thereof and the glycosaminoglycan polymer is one of a pH-labile bond, an acid-labile bond, a base-labile bond, an oxidatively labile bond, a metabolically labile bond, a biochemically labile bond, an enzyme-labile bond, a chemical-labile bond or a photo-labile bond.
[0365] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the releasable linking group is one of an ester group or a nitrobenzene group.
[0366] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the releasable linking group is one of an ester group or a nitrobenzene group and the ethylenically unsaturated reactive group is a methacrylate group.
[0367] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof-containing glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and a side chain comprising a reactive functionality complementary to a reactive functionality of lifitegrast or a salt thereof to provide a lifitegrast or a salt thereof residue grafted onto the polymer backbone.
[0368] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof residue is grafted onto the polymer backbone via an ester bond.
[0369] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof residue is grafted onto the polymer backbone via a nitrobenzene group.
[0370] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof-containing polymer further comprises the ethylenically unsaturated reactive group.
[0371] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the ophthalmic device is a contact lens.
[0372] According to another aspect of the present disclosure, a method comprises:
[0373] (a) applying, to at least a portion of a molding surface of an ophthalmic device mold, the lifitegrast-containing ink binder according to any one of the one or more preceding paragraphs, and
[0374] (b) curing the lifitegrast-containing ink binder to form a lifitegrast-containing film which comprises a polymer network with the one or more of the lifitegrast or salt thereof, the lifitegrast or salt thereof-containing monomer and the lifitegrast or salt thereof-containing polymer in the polymer network, wherein the lifitegrast-containing film contains a first surface in contact with the molding surface and an exposed second surface.
[0375] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the method further comprises:
[0376] dispensing an ophthalmic device-forming mixture comprising an ophthalmic device-forming material into the ophthalmic device mold having the lifitegrast-containing film, and
[0377] curing the ophthalmic device-forming mixture comprising the ophthalmic deviceforming material to form an ophthalmic device, whereby the lifitegrast-containing film detaches from the molding surface and becomes integral with the body of the ophthalmic device thereby producing an ophthalmic device having the lifitegrast-containing film on at least a portion of a surface thereof.
[0378] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the method further comprises:
[0379] releasing the ophthalmic device from the ophthalmic device mold.
[0380] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the ophthalmic device is a silicone contact lens and the method further comprises hydrating the silicone contact lens.
[0381] According to another aspect of the present disclosure, a method for delivering lifitegrast or salt thereof to an eye of a subject comprises:
[0382] (a) placing the ophthalmic device according to any one of the one or more preceding paragraphs, in an eye of a subject, and
[0383] (b) delivering the lifitegrast or salt thereof to the eye of the subject.
[0384] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof is delivered to the eye of the subject by contacting the ophthalmic device having the lifitegrast-containing film on at least the portion ofthe surface thereof with one of light having a wavelength of about 300 nanometers (nm) to about 700 nm or with an esterases or enzymes on the eye, in a tear film or on a flora of the eye.
[0385] In an illustrative embodiment, as may be combined with one or more of the preceding paragraphs, the lifitegrast or salt thereof is delivered to the eye in a sustained release. Various features disclosed herein are, for brevity, described in the context of a single embodiment, but may also be provided separately or in any suitable sub-combination. All combinations of the embodiments are specifically embraced by the illustrative embodiments disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all subcombinations listed in the embodiments describing such variables are also specifically embraced by the present compositions and are disclosed herein just as if each and every such subcombination was individually and explicitly disclosed herein.
[0386] It will be understood that various modifications may be made to the embodiments disclosed herein. Therefore, the above description should not be construed as limiting, but merely as exemplifications of preferred embodiments. For example, the functions described above and implemented as the best mode for operating the present invention are for illustration purposes only. Other arrangements and methods may be implemented by those skilled in the art without departing from the scope and spirit of this invention. Moreover, those skilled in the art will envision other modifications within the scope and spirit of the features and advantages appended hereto.
Claims
CLAIMS1. A lifitegrast-containing ink binder, comprising:(a) a solvent;(b) an ink binder polymer comprising a polymerizable ethylenically unsaturated reactive group; and(c) one or more of a lifitegrast or a salt thereof, a lifitegrast or a salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group and a lifitegrast or a salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group.
2. The lifitegrast-containing ink binder according to claim 1, wherein the ink binder polymer comprises a reaction product of (i) a copolymer comprising (1) monomeric units derived from a hydroxyalkyl acrylate monomer, and (2) monomeric units derived from a hydrophilic monomer having an ethylenically unsaturated reactive group, with (ii) a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive end group.
3. The lifitegrast-containing ink binder according to claim 2, wherein the copolymer comprises (1) monomeric units derived from a hydroxy ethyl acrylate monomer, and (2) monomeric units derived from N-vinylpirrolidone.
4. The lifitegrast-containing ink binder according to claim 2 or 3, wherein the monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive end group is selected from the group consisting of 2-isocyanatoethyl acrylate, 3-isocyanatopropyl acrylate, 2-isocyanatoethyl methacrylate, l-methyl-2-isocyanatoethyl methacrylate, 1, 1-dimethy 1 -2-isocyanatoethyl acrylate, (meth)acryloyl chloride and vinyl chloroformate.
5. The lifitegrast-containing ink binder according to any one of claims 2-4, wherein the copolymer comprises from about 5 mol % to about 95 mol % of the monomeric units derived fromthe hydroxyalkyl acrylate monomer and from about 5 mol % to about 95 mol % of the monomeric units derived from the hydrophilic monomer.
6. The lifitegrast-containing ink binder according to claim 1, wherein the ink binder polymer comprises a silicone prepolymer comprises a reaction product of (i) a copolymerization product of a polymerization composition comprising (1) an alkylacrylamide monomer, (2) a hydroxyalkyl acrylate monomer, (3) a non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive group, and (4) a bulky siloxane monomer having an ethylenically unsaturated reactive group, with (ii) a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive group.
7. The lifitegrast-containing ink binder according to claim 6, wherein the alkylacrylamide monomer is N,N-dimethylacrylamide, the hydroxyalkyl acrylate monomer is a hydroxyethyl acrylate monomer, the non-bulky organosilicon-containing monomer is represented by the following structure:wherein V is ethylenically unsaturated polymerizable group, L is a linker group or a bond; R1, R2, R3, R4, R5, R6, R7, R8, and R9are independently hydrogen an alkyl group, a haloalkyl group, a cycloalkyl group, a heterocycloalkyl group, an alkenyl group, a halo alkenyl group, or an aromatic group; R10and R11are independently hydrogen or alkyl wherein at least one of R10and R11is hydrogen; y is 2 to 7 and n is 1 to 100, or the non-bulky organosilicon-containing monomer is represented by the following structure:wherein R12is H or methyl; X is O or NR16; wherein R16is hydrogen or Ci to C4 alkyl, which may be further substituted with one or more hydroxyl groups; R13is a divalent alkyl group, which may further be functionalized with a group selected from the group consisting of an ether group, a hydroxyl group, a carbamate group and combinations thereof; each R14is independently a phenyl or Ci to C4 alkyl which may be substituted with fluorine, hydroxyl or an ether; R15is a Ci to C4 alkyl; and a is 2 to 50, and the bulky siloxane monomer is represented by the following structure:R18- Si — R18R18wherein X denotes -O- or -NR19- where each R19is hydrogen or a C1-C4 alkyl; R17independently denotes hydrogen or methyl; each R18independently denotes a Ci-Ce alkyl radical, a phenyl radical or a group represented by the following structure:R18'— Si— R18'R18'wherein each R18' independently denotes a Ci-Ce alkyl radical or a phenyl radical; and h is 1 to 10; or the following structure:R18R1— Si — R18wherein X denotes -NR19-; wherein R19denotes hydrogen or a C1-C4 alkyl; R17denotes hydrogen or methyl; each R18independently denotes a Ci-Ce alkyl radical, a phenyl radical or a group represented by the following structure:R18'— Si— R18'R18'wherein each R18' independently denotes a Ci-Ce alkyl radical or a phenyl radical; and h is 1 to 10.
8. The lifitegrast-containing ink binder according to claim 6 or 7, wherein the monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate monomer and a polymerizable ethylenically unsaturated reactive end group is selected from the group consisting of 2-isocyanatoethyl acrylate, 3-isocyanatopropyl acrylate, 2-isocyanatoethyl methacrylate, l-methyl-2-isocyanatoethyl methacrylate, 1, 1-dimethy 1 -2-isocyanatoethyl acrylate, (meth)acryloyl chloride and vinyl chloroformate.
9. The lifitegrast-containing ink binder according to any one of claims 6-8, wherein the silicone prepolymer comprises:from about 50 to about 400 repeating units of monomeric units derived from the alkylacrylamide monomer;from about 50 to about 200 repeating units of monomeric units derived from the hydroxyalkyl acrylate monomer;from about 5 to about 20 repeating units of monomeric units derived from the hydroxyalkyl acrylate monomer where the acrylate moiety is attached to the backbone of the copolymer and the hydroxy moiety is end functionalized with a monomer having a reactive functionality complementary to the hydroxyl moiety of the hydroxyalkyl acrylate and a polymerizable ethylenically unsaturated reactive end group;from about 20 to about 300 repeating units of monomeric units derived from the non-bulky organosilicon-containing monomer having an ethylenically unsaturated reactive end group; and from about 1 to about 400 repeating units of monomeric units derived from the bulky siloxane monomer having an ethylenically unsaturated reactive end group.
10. The lifitegrast-containing ink binder according to any one of claims 1-9, wherein the releasable linking group of the lifitegrast or a salt thereof-containing monomer is an ester group.
11. The lifitegrast-containing ink binder according to any one of claims 1-9, wherein the releasable linking group of the lifitegrast or a salt thereof-containing monomer is a nitrobenzene group.
12. The lifitegrast-containing ink binder according to any one of claims 1-9, wherein the one or more of a lifitegrast or a salt thereof, the lifitegrast or salt thereof-containing monomer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group or the lifitegrast or salt thereof-containing polymer comprising a releasable linking group and optionally an ethylenically unsaturated reactive group is the lifitegrast or salt thereof.
13. The lifitegrast-containing ink binder according to any one of claims 1-9, wherein the lifitegrast or salt thereof-containing polymer comprises a lifitegrast or a salt thereof-containing glycosaminoglycan polymer.
14. The lifitegrast-containing ink binder according to claim 13, wherein the lifitegrast or salt thereof-containing glycosaminoglycan polymer comprises lifitegrast or a salt thereof attached to a glycosaminoglycan polymer via a releasable linking group.
15. The lifitegrast-containing ink binder according to claim 13 or 14, wherein the lifitegrast or salt thereof-containing glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and a side chain comprising a reactive functionality complementary to a reactive functionality of lifitegrast or a salt thereof to provide a lifitegrast or a salt thereof residue grafted onto the polymer backbone.
16. The lifitegrast-containing ink binder according to claim 15, wherein the lifitegrast or salt thereof residue is grafted onto the polymer backbone via an ester bond or a nitrobenzene group.
17. An ophthalmic device comprising a lifitegrast-containing film on at least a portion of a surface thereof, the lifitegrast-containing film comprising a polymerization product of the lifitegrast-containing ink binder according to any one of claims 1-16.
18. The ophthalmic device according to claim 17, wherein the one or more of the lifitegrast or salt thereof, the lifitegrast or salt thereof-containing monomer and the lifitegrast or a salt thereof-containing polymer are embedded in the polymerization product.
19. The ophthalmic device according to claim 17 or 18, which is a contact lens.
20. A method, comprising:applying, to at least a portion of a molding surface of an ophthalmic device mold, the lifitegrast-containing ink binder according to any one of claims 1-17; andcuring the lifitegrast-containing ink binder to form a lifitegrast-containing film which comprises a polymer network with the one or more of the lifitegrast or salt thereof, the lifitegrast or salt thereof-containing monomer and the lifitegrast or salt thereof-containing polymer in the polymer network, wherein the lifitegrast-containing film contains a first surface in contact with the molding surface and an exposed second surface.
21. The method according to claim 20, further comprising:dispensing an ophthalmic device-forming mixture comprising an ophthalmic deviceforming material into the ophthalmic device mold having the lifitegrast-containing film; and curing the ophthalmic device-forming mixture comprising the ophthalmic deviceforming material to form an ophthalmic device, whereby the lifitegrast-containing film detaches from the molding surface and becomes integral with the body of the ophthalmic device thereby producing an ophthalmic device having the lifitegrast-containing film on at least a portion of a surface thereof.
22. The method according to claim 21, further comprising:releasing the ophthalmic device from the ophthalmic device mold.
23. The method according to claim 21 or 22; wherein the ophthalmic device is a silicone contact lens and the method further comprises hydrating the silicone contact lens.
24. A method for delivering lifitegrast or salt thereof to an eye of a subject comprising:placing the ophthalmic device according to any one of claims 17-19 in an eye of a subject; anddelivering the lifitegrast or salt thereof to the eye of the subject.
25. The method according to claim 24, wherein the lifitegrast or salt thereof is delivered to the eye of the subject by contacting the ophthalmic device having the lifitegrast-containing film on at least the portion of the surface thereof with one of light having a wavelength of about 300 nanometers (nm) to about 700 nm or with an esterases or enzymes on the eye, in a tear film or on a flora of the eye.
26. The method according to claim 25, wherein the lifitegrast or salt thereof is delivered to the eye of the subject in a sustained release.
